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SUMMARY 
The Hippo pathway coordinates extracellular signals onto the control of tissue homeostasis and 
organ size.  Hippo signaling primarily regulates the ability of Yap1 to bind and co-activate TEA 
domain (TEAD) transcription factors.  Yap1 tightly binds to TEAD4 via a large flat interface making 
the development of small-molecule orthosteric inhibitors highly challenging.  Here, we report 
small-molecule TEAD•Yap inhibitors that rapidly and selectively form a covalent bond with a 
conserved cysteine located within the unique deep hydrophobic palmitate binding pocket of 
TEADs.  Inhibition of TEAD4 binding to Yap1 by these compounds was irreversible and occurred 
on a longer timescale.  In mammalian cells, the compounds formed a covalent complex with 
TEAD4, inhibited its binding to Yap1, blocked its transcriptional activity, and suppressed 
expression of connective tissue growth factor (CTGF).  The compounds inhibited cell viability of 
patient-derived glioblastoma spheroids making them suitable as chemical probes to explore Hippo 
signaling in cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
The Hippo signaling pathway controls tissue homeostasis and organ size (Wu, et al., 2003). Hippo 
is triggered by an NF2/Merlin-Kibra-Expanded tumor suppressor complex that activates the 
Ste20-like kinase, Hippo (Mst1/2 in mammals), which then phosphorylates and activates the large 
tumor suppressor kinases (Lats1/2). Lats1/2 kinases, in turn, phosphorylate the transcriptional 
co-activators Yap and TAZ to promote their cytoplasmic retention and degradation (Yu and Guan, 
2013). Lack of cell crowding coupled with mechanical loading such as stretching, location at 
edges of an epithelial sheet, or stiffness of the surrounding extracellular matrix (ECM) are factors 
that promote Yap/TAZ (Aragona, et al., 2013) to enter the nucleus where they co-activate TEAD 
transcription factors (Hong and Guan, 2012; Mauviel, et al., 2012; Pobbati and Hong, 2013; Yu 
and Guan, 2013).  In mammals, there exists four highly conserved TEAD/TEF transcription 
factors, namely TEAD1-4 (Eldridge, et al., 1997).  The average sequence identity among TEADs 
is 73%, which is considered high (Noland, et al., 2016).  TEADs possess similar domains:  an N-
Terminus DNA-binding TEA/ATTS domain (Anbanandam, et al., 2006), and a C-terminus 
immunoglobulin-like β-sandwich fold (Pobbati, et al., 2012).  TEADs alone cannot initiate gene 
expression; they rely on co-activators such as Yap and its paralog TAZ, as well as vestigial-like 
proteins (VGLL), and the p160 family of nuclear receptor co-activators (Hong and Guan, 2012; 
Pobbati and Hong, 2013). Activation of TEADs initiates expression of CCN matricellular growth 
factors, such as connective tissue growth factor (CTGF), Cyr61, EGF receptor ligand 
amphiregulin (AREG), and Axl receptor tyrosine kinase (Fridell, et al., 1996; Mauviel, et al., 2012; 
Piccolo, et al., 2013; Rosell, et al., 2013; Yu, et al., 2012).  Expression of these growth factors 
leads to cell growth, apoptotic avoidance, and stem cell self-renewal (Hong and Guan, 2012; 
Piccolo, et al., 2013; Yu and Guan, 2013). 
 Despite substantial evidence that Yap1 promotes tumor progression and metastasis 
through its TEAD-interaction domain (Liu-Chittenden, et al., 2012; Zhao, et al., 2008), no small 
molecules have been identified that directly disrupt this interaction.  The approved drug 
verteporfin, which was identified by high-throughput screening to impair Hippo signaling (Liu-
Chittenden, et al., 2012), has not been demonstrated to physically associate with either TEAD or 
Yap.  Instead, recent work indicates that verteporfin works through other mechanisms, including 
the inhibition of p62 (Donohue, et al., 2014; Donohue, et al., 2013; Donohue, et al., 2011). Cyclic 
Yap-like peptides (Zhou, et al., 2015) and recombinant proteins such as vestigial-like proteins 
(VGLL), have been used to disrupt the interaction of TEAD with Yap1 in vitro.   VGLL, which 
directly compete with Yap1 for a common binding site on TEAD, also were found to negatively 
regulate TEAD/Yap activity and to suppress lung and gastric tumor activity (Zhang, et al., 2014). 
Along these lines, a peptide that mimics the TDU domain of VGLL4 was found to suppress tumor 
growth in gastric cancer cells both in vitro and in vivo (Jiao, et al., 2014). Small interfering RNA-
lipid nanoparticles (siRNA-LNPs) that target Yap1 have also been shown to decrease liver tumor 
proliferation (Fitamant, et al., 2015). While upstream regulators of Hippo signaling such as GPCRs 
and kinases are amenable to small-molecule inhibition (Fan, et al., 2013; Reddy and Irvine, 2013; 
Yu, et al., 2012), their prominence in other signaling pathways will likely result in off-target effects.   
 The three-dimensional structure of the TEAD•Yap complex (Chen, et al., 2010; Li, et al., 
2010) reveals that disruption of the protein-protein interaction is expected to be difficult. The 
interaction interface between TEAD•Yap is unusually large, exceeding 1000 Å2 (Chen, et al., 
2010).  It is devoid of a well-defined druggable binding pocket. The large interface and lack of 
binding site likely explains the failure to develop agents that competitively inhibit the TEAD•Yap 
interaction. Alternatively, a deep hydrophobic palmitate binding pocket within all TEAD members 
has been shown to be important for their stability but not their biological activity (Chan, et al., 2016; 
Noland, et al., 2016). All TEAD paralogs are palmitoylated at a conserved cysteine located within 
this pocket (Noland, et al., 2016).  Considering that the palmitate pocket is located away from the 
TEAD•Yap interface, it has been suggested that palmitoylation allosterically alters TEAD to 
stabilize an interaction with Yap (Chan, et al., 2016; Noland, et al., 2016).  Thus, targeting the 
palmitate binding pocket may be an effective strategy for modulating the interaction of TEAD with 
Yap. 
 Here we report the discovery of small molecules that bind to the TEAD4 palmitate pocket, 
form a covalent bond with a conserved cysteine, and disrupt the TEAD4•Yap1 protein-protein 
interaction. Starting with the structure of flufenamic acid bound to TEAD2 (Pobbati, et al., 2015) 
we designed a small molecule that can form a covalent bond with a conserved cysteine within the 
palmitate binding pocket.  Extensive explicit-solvent molecular dynamics simulations revealed 
that covalent bond formation of this compound reduced the TEAD4•Yap1 binding affinity.  
Synthesis of this compound and several derivatives followed by biochemical studies that 
characterized binding affinity and inhibition kinetics confirmed the computational results.  
Compounds were explored for their effect on TEAD4 protein-protein interactions and 
transcriptional activity in HEK-293 mammalian cells, as well as in glioblastoma (GBM) cancer cell 
lines.   
 
RESULTS 
Molecular Dynamics Simulations Reveal that Covalent Bond Formation at Allosteric 
Pocket Cysteine Reduces TEAD4•Yap1 Affinity.  The TEAD three-dimensional structure 
contains a 12-strand β-sandwich fold, flanked by four short α-helices (Fig. 1A). The N-terminal 
region of Yap1 (residues 61-100) forms an α-helix (residues 61-73), which binds between TEAD 
α3 and α4 helices, and an Ω-loop (residues 85-99), which binds near TEAD α1 and β12 (Fig. 1A).  
Crystal structures of TEADs reveal the presence of a deep hydrophobic pocket that is occupied 
by palmitate (Fig. 1B) (Pobbati, et al.).  The FDA-approved drug flufenamic acid 1 (TED-346) was 
previously found to bind weakly to two sites on TEAD2, but it did not inhibit TEAD binding to Yap  
(Pobbati, et al., 2015).  One of the binding sites is located within the deep hydrophobic palmitate-
binding pocket of the transcription factor and the other at the protein-protein interaction interface 
(Pobbati and Hong).  The binding mode of 1 (TED-346) in the deep pocket of TEAD2 shows that 
the compound’s carboxylic acid moiety is located near the thiol of a conserved cysteine residue 
(Cys-367) that is the acylation site of a palmitoyl group (Chan, et al., 2016).  We hypothesized 
that modification of the carboxylic acid to an electrophile may lead to covalent adduct formation 
and modulation of the TEAD4•Yap1 protein-protein interaction.  Considering that the palmitate 
pocket is located outside the TEAD4•Yap1 protein-protein interaction interface, it was not obvious 
whether adduct formation would stabilize or inhibit the TEAD4•Yap1 protein-protein interaction.  
To explore the effect of adduct formation on the TEAD4•Yap1 interaction, we designed a 
derivative of compound 1, namely 2 (TED-347), which possesses a chloromethyl ketone moiety 
that can form a covalent bond with Cys-367.  We applied microsecond explicit-solvent molecular 
dynamics simulations to determine whether covalent bond formation at the cysteine residue 
affects TEAD4•Yap1 protein-protein interaction.  We carried out three separate simulations: 
TEAD4•Yap1; [TEAD4•2]•Yap1 non-covalent complex (Fig. 1C); and [TEAD4-2]•Yap1 covalent 
complex (Fig. 1D).  Each simulation consisted of 50 separate 50-ns trajectories resulting in 2.5 
µs (50 × 50 ns) of explicit-solvent molecular dynamics simulations per complex. Structures 
sampled from these simulations were collected to determine the free energy of binding of TEAD4 
to Yap1 in each of the complexes using the widely-used MM-GBSA free energy calculation 
method (Fig. 1E).  We found that non-covalent binding of 2 (TED-347) to TEAD4 exhibited little 
change to the TEAD4•Yap1 binding affinity (∆∆GMMPBSA = 0.5 ± 0.1 kcal/mol).  However, covalent 
adduct formation of 2 (TED-347) to TEAD4 led to substantially greater loss of TEAD4 affinity to 
Yap1 by nearly 10.9 ± 0.1 kcal/mol (Fig. 1F).  The 20-fold reduction in the binding affinity suggests 
that adduct formation at Cys-367 leads to allosteric inhibition of the TEAD4•Yap1 protein-protein 
interaction.  These results were confirmed by repeating the calculations with compound 5 (TED-
551).  Non-covalent binding of the compound led to little change for the affinity of the TEAD4•Yap1 
complex (∆∆GMMGBSA = -0.5 ± 0.1 kcal/mol), while covalent bond formation led to substantial 
reduction in the MM-GBSA binding affinity to 5.3 ± 0.1 kcal/mol (Fig. 1F).  These results suggest 
that mere binding to the pocket is not sufficient to disrupt the protein-protein interaction, whereas 
covalent bond formation with the cysteine residue may lead to inhibition of the interaction. 
Compound 2 and Derivatives Form Covalent Adducts at an Allosteric Site and Inhibit 
TEAD4 Binding to Yap1.  Chloromethyl ketone 2 (TED-347) (Fig. 2) was prepared to determine 
whether it formed a covalent complex with TEAD4.  To explore direct binding of the compounds 
to TEAD4, we developed a fluorescence polarization assay that used a fluorescently-labeled 
Yap1-derived peptide FAM-YAP60-99 (FAM-
DSETDLEALFNAVMNPKTANVPQTVPMCLRKLPASFCKPP).  FAM-YAP60-99 includes the entire 
Yap1•TEAD4 binding interface (Fig. 3A).  The labeled peptide binds to TEAD4 with a KD of 78.2 
± 9.9 nM.  Compound 1 (TED-346, flufenamic acid)  was tested and we found that the drug did 
not inhibit the TEAD4•Yap1 interaction, consistent with previous studies (Fig. 3B).  The effects of 
other compounds on the TEAD4•Yap1 interaction were tested using our fluorescence polarization 
assay. Following 24 h incubation of TEAD4 with 2 (TED-347) at 4°C, the compound inhibited the 
TEAD4•Yap1 protein-protein interaction by 53% with an apparent EC50 of 5.9 ± 0.4 µM (Fig. 3B). 
Compound 3 (TED-550) did not inhibit, as the compound cannot form a covalent adduct since the 
chlorine atom leaving group is replaced by a methyl group (Fig. 3B). A time-dependent study was 
performed at 0.5, 6, 24 and 48 h for 2 (TED-347) (Fig. 3C), where 2 (TED-347) reached maximum 
inhibition of 80% at 48 h. Based on the time- and concentration-dependent inhibition study of 
TEAD4 with 2 (TED-347) (Fig. 3D), the rates of inactivation were calculated for the compounds 
and several derivatives (Supp. Table S1). The maximum rate of inactivation of 2 (TED-347) was 
calculated to be 0.038 ± 0.003 h-1 (Fig. 3D), corresponding to a 𝑡𝑡1/2∞  of 18.2 h. To determine if 2 
(TED-347) is a reversible or irreversible inhibitor, TEAD4 was incubated with 50 µM compound 
for 24 h at 4 °C, and then dialyzed against buffer for 24 h at 4 °C, prior to interaction with the 
fluorescently labeled Yap1 peptide (Fig. 3E).  Compound 2 (TED-347) inhibited the TEAD4•Yap1 
interaction, even after dialysis, indicating the compound is an irreversible inhibitor. 
 The formation of a covalent bond between compounds and TEAD4 was confirmed by 
whole protein ESI mass spectrometry studies. Following incubation of TEAD4 at 10 µM with 200 
µM of 2 for 24 h at 4 °C, a peak at 26229 was observed, corresponding to the TEAD4•2 (TED-
347) adduct, while the peak at 25952 corresponding to TEAD4 disappeared (Fig. 3F). As 
expected, compound 3 (TED-550) only showed a peak at 25952 indicating no adduct formation. 
The covalent adduct formation by 2 (TED-347) was relatively fast (Fig. 3G), reaching nearly 100% 
adduct formation after 30 min incubation with TEAD4. Because the rate of inhibition developed 
over a longer timescale (Fig. 3C), 2 (TED-347) is proposed to induce a slow conformational 
change in TEAD4 that prevents its interaction with Yap1. To rule out the possibility that 2 (TED-
347) induces slow aggregation of TEAD4, and not the proposed slow conformational change, we 
incubated GST-TEAD4 with DMSO or TED-347 for 24 h at 4 °C, followed by injection into a SEC 
column (Fig. 3H). There is no significant aggregation of GST-TEAD4 after 24 h incubation, with 
or without 2 (TED-347). A slight increase in dimer formation for the TEAD4 sample incubated with 
2 (TED-347) compared to the sample incubated with DMSO. In addition, we notice a slight shift 
in the retention time of the TEAD4 sample incubated with 2 (TED-347), as well as peak 
broadening, compared to the TEAD4 incubated with DMSO, both of which suggest conformational 
change of the protein. Furthermore, it is highly unlikely that Cys-367 oxidation is responsible for 
the lack of 100% inhibition at longer times since we have shown that covalent bond formation is 
rapid and complete within less than an hour. Also, whole protein mass spectrometry carried out 
at 24 h does not reveal the presence of the oxidized species.   
 To further establish that compound 2 specifically forms a bond with Cys-367, within the 
central pocket of TEAD4, we tested its interaction with a TEAD4 Cys367Ser mutant.  Adduct 
formation by 2 (TED-347) to the mutant TEAD4 Cys367Ser was analyzed by mass spectrometry. 
After 24 h, 2 (TED-347) did not form an adduct with the mutant protein (Fig. 4A). TEAD4 
Cys367Ser mutant showed no change in affinity for FAM-YAP60-99 peptide, with a KD of 49.1 ± 3.0 
nM (Fig. 4B). Subsequently, the compounds were tested for inhibition of the peptide binding to 
TEAD4.  We found that 2 (TED-347) did not inhibit the mutant TEAD4 Cys367Ser protein binding 
to the peptide, suggesting that covalent adduct formation by 2 (TED-347) is essential for its ability 
to inhibit the protein-protein interaction (Fig. 4C). 
We explored whether mere covalent bond formation with conserved Cys-367 was 
sufficient to inhibit the TEAD4•Yap1 protein-protein interaction. ESI mass spectrometry was used 
to detect formation of adducts by iodoacetamide. In <30 minutes, we saw a concentration-
dependent adduct formation up to 200 µM, where the protein was modified by a single adduct 
(Supp. Fig. 1A). After 6 h, the protein was modified by a single adduct at all concentrations of 
iodoacetamide (Supp. Fig. 1B). We did not see presence of a second reaction site until 24 h at 
the highest tested concentration of 200 µM (Supp. Fig. 1C). To determine whether Cys-367 is 
the target of the single adduct, we reacted TEAD4 Cys367Ser mutant with varying concentrations 
of iodoacetamide for 24 h. After 24 h, there was no modification of the protein, except for a small 
adduct that was detected only at 200 µM iodoacetamide concentration, which is consistent with 
the wild-type TEAD4 (Supp. Fig. 1D). Although iodoacetamide is able to react with TEAD4 Cys-
367, it was unable to inhibit the activity of the protein in the FP assay (Supp. Fig 1E). Thus, 
merely reacting with the cysteine does not guarantee inhibition of activity. 
 To further confirm that 2 (TED-347) inhibited the interaction between TEAD4 and Yap1 
peptide observed in our fluorescence polarization assay, we applied biolayer interferometry (BLI) 
that used full-length Yap1 protein.  The binding affinity between GST-tagged Yap1 and the TEAD4 
protein was found to be 116.5 ± 5.9 nM (Fig. 4D), which was comparable to that of the FAM-
YAP60-99 peptide. As with the peptide fluorescence polarization assay, TEAD4 was incubated with 
2 (TED-347) for 24 or 48 h at 4 °C prior to studying its interaction with GST-Yap1 using BLI. As 
with the FP assay, we observed dose- and time-dependent inhibition of TEAD4 binding to full-
length Yap1 (Fig. 4E). 
 Since the palmitate-binding pocket and the Cys-367 residue is conserved in all 4 human 
TEAD proteins, we tested whether 2 (TED-347) would be active against TEAD2. His-tagged 
TEAD2 protein was tested in the FP binding assay, where it showed an apparent Kd of 27.6 ± 1.7 
nM (Fig. 4F). Compounds 1-3 were incubated with TEAD2 for 24 h at 4 °C prior to the addition of 
the Yap1 peptide, and compound 2 (TED-347) was shown to inhibit TEAD2, while 1 (TED-346) 
and 3 (TED-550) were inactive as expected (Fig. 4G).  We expect that compound 2 (TED-347) 
will likely inhibit protein-protein interactions of TEAD1 and TEAD3 with Yap1 considering their 
close structural similarity to TEAD4. 
 The selectivity of the compounds was explored with two unrelated protein-protein 
interactions between (i) the urokinase receptor (uPAR) and its ligand urokinase (uPA); and (ii) the 
α subunit of the voltage-gated calcium channel Cav2.2 with its β subunit Cavβ3.  We have 
previously developed fluorescence polarization assays for these interactions as we have reported 
for uPAR (Mani, et al., 2013). 2 (TED-347) and 3 (TED-550) showed no inhibition of uPAR•uPA 
or Cav2.2 α•β protein-protein interactions (Fig 4H and I).  Both proteins have cysteine residues 
capable of forming covalent adducts.  These results further confirm the selectivity of compound 2 
(TED-347). 
Structure of 2 (TED-347) in complex with TEAD2. A TEAD2•2 complex was formed by soaking 
TEAD2 crystals with 2 (TED-347). The crystal diffracted to 2.43 Å resolution, and the structure 
was solved in space group C2 with two TEAD2 per asymmetric unit (Supp. Table 2). The overall 
structure of TEAD2 in complex with 2 (TED-347) is the same as previously published structures, 
with a Cα RMSD of 0.59 Å, compared to a previously published structure (PDB ID: 5DQ8). The 
density of 2 (TED-347) within the central binding site is weak (Fig. 5A), possibly indicating less 
than 100 % occupancy. To confirm that the observed density is 2 (TED-347) and not palmitate, 
we soaked out the fatty acid by incubating the crystal in a buffer containing DTT for 2 h. There is 
no density within the central pocket after this treatment. We performed a 3-step soaking 
experiment, where the crystal was first soaked in buffer containing DTT for 2 h to remove the fatty 
acid, then exchanged into buffer without DTT for 2 h, and finally incubated with 2 (TED-347) for 
3-4 h. The crystal quality suffered after the treatment, but an unambiguous positive density was 
observed in the pocket, covalently attached to Cys-380. Compared to the structure of TEAD2 in 
complex with 1 (PDB ID: 5DQ8), the first benzene ring of 2 (TED-347) is rotated away from the 
direction of Val-347 by about 90° to allow the covalent bond to form. The second ring and the 
trifluoromethyl group is shifted further into the hydrophobic pocket (Fig. 5A and B). However, it is 
possible to say, due to our multi-step soaking experiment and the resulting positive density, we 
can visibly see that 2 (TED-347) forms a covalent bonded interaction with TEAD2 at our proposed 
site of Cys-380. 
Synthesis and Biochemical Studies of Compound 2 (TED-347) Derivatives. Five derivatives 
of 2 (TED-347) were synthesized (Fig. 2). 4 (TED-548) was designed to more closely mimic 
palmitate, with an elongated PEG-like moiety, which we hypothesized could improve the binding 
affinity of the compound. 5 (TED-551) was designed to improve the reactivity of the compound, 
as an electron-withdrawing nitrogen atom was added to the aromatic ring bearing the 
chloromethyl ketone group. 6 (TED-589) was designed to improve the affinity and selectivity of 2 
(TED-347) against TEAD4 by exploiting the nearby pocket. Compounds 7 (TED-587) and 8 (TED-
588) were designed to improve the affinity of the compound based on docking studies. After 24 h 
incubation with TEAD4 at 4 °C, 4 (TED-548), 5 (TED-551), and 6 (TED-589) showed a maximum 
inhibition of 31, 81, and 51% respectively, while 7 (TED-587) and 8 (TED-588) displayed less than 
20% inhibition (Supp. Fig. S2A). Yet, the EC50 of compound 4 (TED-548) was substantially lower 
(nearly an order of magnitude) than its parent 2 (TED-347), as well as the other derivatives. It is 
worth noting that 5 (TED-551) also inhibited the TEAD4 Cys367Ser mutant, in contrast to 4 (TED-
548) and 6 (TED-589) (Supp. Fig. S2B). 6 (TED-589) had improved EC50 of 2.3 ± 0.8 µM, while 
still being selective toward Cys-367. Whole protein mass spectrometry analysis of TEAD4 with 
the compounds showed that 4 (TED-548), 6 (TED-589), 7 (TED-587) and 8 (TED-588) formed 
single adducts, consuming all of the protein, while 5 (TED-551) formed more than one covalent 
complex (Supp. Fig. S2C). Furthermore, only 5 (TED-551) formed an adduct with the TEAD4 
Cys367Ser mutant as evidenced by a minor peak corresponding to a mass of 26217 (Supp. Fig. 
S2D). The lack of TEAD4 inhibition by 7 (TED-587) and 8 (TED-588) (Supp. Fig. S2A), while still 
forming 100% adduct with TEAD4 (Supp. Fig. S2C), again demonstrates that mere binding and 
reaction to Cys-367 on TEAD4 is not sufficient for inhibition of TEAD4 activity, as demonstrated 
with iodoacetamide (Supp. Fig. S1). The five derivatives were also tested for inhibition of TEAD2 
binding to Yap1. Compound 5 (TED-551) showed similar inhibition of TEAD2 and TEAD4 binding 
to Yap1, while 4 (TED-548) and 6 (TED-589) were much weaker inhibitors of TEAD2 compared 
to TEAD4 (Supp. Fig. S2E).  
 The three active derivatives showed concentration- and time-dependent inhibition of 
TEAD4 (Supp. Fig. S2 F-H). The rate of inactivation of 4 (TED-548) is lower than its parent at 
0.010 ± 0.001 h-1, which resulted in a 𝑡𝑡1/2∞  of 67.3 h (Supp. Fig. S2I). The rate of inactivation of 5 
(TED-551) is slightly faster than its parent with a kinact of 0.049 ± 0.003 h-1 corresponding to a half-
life of 14.3 h (Supp. Fig. S2J). The rate of inactivation of 6 (TED-589), kinact = 0.034 ± 0.003 h-1 
(𝑡𝑡1/2∞  = 20 h) (Supp. Fig. S2K), was similar to the parent 2 (TED-347). 
Small Molecules Inhibit TEAD Transcriptional Activity and Protein Interactions in Cells. 
The effect of 2 (TED-347) on the intracellular transcriptional activity of TEAD4 was compared to 
its effects on the interaction of TEAD4 with Yap (Fig. 6). Treatment of cells transfected with a 
TEAD reporter over 48 h with compound 2 at 5 µM resulted in over 70% reduction in reporter 
activity, whereas cells treated with 10 µM of 2 showed a complete loss of reporter activity. Less 
activity is observed at 24 h suggesting time-dependent activity in cells (Fig. S3A).  To further 
establish the selectivity of the small molecule, we repeated the TEAD4 transcriptional activity 
luciferase reporter assays using instead transfected Cys367Ala mutant.  We found that treatment 
of HEK-293 cells with 2 (TED-347) did not result in the inhibition of TEAD4 transcriptional activity 
as was observed for wild-type TEAD4 (Fig. S3B).  Consistent with these effects being a result of 
disruption of the TEAD4•Yap1 interaction, cells incubated with 5 µM of 2 (TED-347) showed a 
significant loss of co-immunoprecipitation of Myc-tagged TEAD4 with Flag-Tagged Yap1 (Fig. 6A, 
B and C).  To establish that 2 (TED-347) forms a covalent adduct with TEAD4 in cells, a biotin-
conjugated variant termed 9 (TED-549) was synthesized. Following addition of 9 (TED-549) to 
cell lysates, TEAD4 was specifically detected by immunoblot analysis in a streptavidin pull-down, 
consistent with compound 2 (TED-347) directly engaging TEAD4 in cells in a covalent complex 
(Fig. 6D, 6E, and S3B). The reduction in TEAD4 in 9 (TED-549) containing samples that were 
also treated with higher concentrations of 2 (TED-347) or 5 (TED-551) indicates that these 
compounds compete with 9 (TED-549) for binding to TEAD4 (Fig. 6D and 6E lanes 3 and 4). To 
monitor endogenous TEAD activity, the levels of CTGF transcript (a well-established target of 
TEAD) were measured by qRT-PCR from control cells and cells incubated with compound 2 
(TED-347) or 5 (TED-551).  Cells incubated with compounds 2 (TED-347) and 5 (TED-551) 
showed a significant reduction in CTGF transcript levels versus control cells (Fig. 6F).  Cells 
incubated with compound 3 (TED-550), which lacks the reactive moiety necessary to form an 
adduct with TEAD4, showed similar levels of CTGF transcript versus control cells. 
Compounds Inhibit GBM Cancer Cell Viability.  Hippo signaling promotes tumor growth and 
invasion in a range of cancers including GBM (Artinian, et al., 2015; Orr, et al., 2011; Shah, et al., 
2014).  We investigated the effects of 1, 2 and 5 on GBM cell viability using patient-derived 
GBM43 cells that were grown as three-dimensional spheroids (Fig. 7A).  Both 2 (TED-347) and 
5 (TED-551) inhibited GBM43 cancer cell viability.  At 10 µM, which is the concentration that was 
used to demonstrate inhibition of TEAD4 activity in cells, the compounds inhibit GBM43 cell 
viability by 30%.  At this concentration, the compound did not show any effect on cell viability of 
non-transformed normal astrocytes (Fig. S4).  Compound 1 (TED-346), which does not inhibit 
TEAD4•Yap1, did not affect GBM43 cancer cell growth (Fig. 7A).  Compound 2 (TED-347) also 
inhibited TEAD4 transcriptional activity in GBM43 cells (Fig. 7B) in a concentration-dependent 
manner.  Similarly, as shown in Fig. 7C, both 2 (TED-347) and 5 (TED-551) suppressed CTGF 
transcript levels while 1 (TED-346) had no effect versus cells treated with vehicle.   The potency 
of compounds 2 (TED-347) and 6 (TED-551) were compared to temozolomide, which is the 
standard of care for patients with glioblastoma.  Temozolomide inhibited GBM43 spheroid growth 
with a substantially higher EC50 of 244 ± 24 µM (Fig. 7D).  
DISCUSSION 
The intense interest in Hippo signaling has highlighted the need for small-molecule probes to 
explore the pathway in normal and pathological processes.  However, the development of 
orthosteric small-molecule inhibitors of the TEAD•Yap interaction has not been successful, likely 
due to this interaction occurring over a large and featureless binding interface (1300 Å2) with a KD 
in the nanomolar range. While the drug verteporfin was initially proposed to inhibit the TEAD•Yap 
interaction, it has not been shown to directly bind either TEAD or Yap.  Its effects have 
subsequently been attributed to interactions with other unknown proteins. A crystal structure of 
TEAD2 bound to flufenamic acid (Pobbati, et al., 2015) shows that the FDA-approved drug binds 
to two sites:  (i) The palmitate pocket and (ii) the TEAD•Yap interface.  Flufenamic acid binds 
weakly to TEAD2 and does not inhibit its interactions as reported earlier and confirmed in this 
work. 
The three-dimensional structures of TEADs reveal a conserved cysteine (Cys-367) deep within 
the palmitate binding pocket of TEAD4.  Cys-367 spontaneously forms an adduct to palmitoyl-
CoA (Chan, et al., 2016; Noland, et al., 2016) resulting in stability of the TEAD•Yap complex 
(Mesrouze, et al.).  Since palmitate does not come in contact with Yap, the process is believed to 
occur through an allosteric mechanism.  This prompted us to postulate that a small molecule that 
forms a covalent bond with Cys-367 may modulate the TEAD protein-protein interaction with Yap.  
To test this, we modified flufenamic acid by introducing a reactive chloromethyl ketone moiety 
and used microsecond explicit-solvent molecular dynamics simulations followed by free energy 
calculations to investigate the effect of adduct formation on the protein-protein complex.  These 
substantial calculations revealed that non-covalent binding of compounds led to negligible change 
in the MM-GBSA free energy of the TEAD4•Yap1 complex, whereas covalent bond formation with 
Cys-367 led to substantial weakening of the interaction. To test this hypothesis, compound 2 
(TED-347) was prepared and found to inhibit the protein-protein interaction in a time-dependent 
manner.  Biochemical studies confirmed that 2 (TED-347) formed a covalent bond with Cys-367 
with a binding affinity of KI = 10.3 ± 2.6 µM and an inactivation rate constant of kinact = 0.038 ± 
0.003 h-1, which corresponds to a half-life 𝑡𝑡1/2∞  of 18 h.The compound is selective for TEADs as 
shown by its ability to inhibit TEAD2 with the same efficacy, while not being able to inhibit 
unrelated protein-protein interactions, uPAR•uPA and Cav2.2β3•AID. Synthesis of several 
derivatives afforded a structure-activity study and the discovery of three compounds: one that 
exhibited higher affinity but poorer rate of inactivation (compound 4), better inhibition rate and 
similar affinity (compound 5), and higher affinity while maintaining a similar rate of inactivation 
(compound 6).  In each case, covalent modification of Cys-367 led to inhibition of the 
TEAD4•Yap1 protein-protein interaction.  Whole protein mass spectrometry revealed that adduct 
formation of TEAD4 with 2 (TED-347) was complete within a few minutes, in contrast to the hours 
required to inhibit the TEAD4•Yap1 protein-protein interaction.  The covalent bond formation is 
therefore not the event that leads to inhibition of the protein-protein interaction.  This is further 
confirmed by studies with iodoacetamide as well as compounds 7 and 8, all of which readily form 
adducts to TEAD4 but do not inhibit its interaction with Yap1.  Covalent bond formation likely leads 
to local conformational changes that are followed by large-scale conformational and dynamical 
changes that favor TEAD4 conformational states that are not suitable for complex formation with 
Yap1. Comparison of the three-dimensional structure of the non-covalent and covalent complex 
of 2 (TED-347) with TEAD4 shows that the benzene ring bearing the reactive warhead adopts a 
different conformation in the covalent complex.  This structure may shift the conformation of 
TEAD4 that leads to inhibition of the TEAD4•Yap1 complex.   
Compound 2 (TED-347) was then shown to functionally disrupt the TEAD•Yap1 interaction in cells 
and to reduce the viability of patient-derived glioblastoma cell lines. Previous studies have shown 
that Hippo plays a major role in promoting GBM growth and invasion (Artinian, et al., 2015; Orr, 
et al., 2011; Shah, et al., 2014).  HEK-293 and low-passage patient-derived GBM43 cells treated 
with compound 2 (TED-347) were found to have reduced TEAD4 transcriptional activity and to 
lack protein-protein complexes between TEAD4 and Yap1.  Pull-down studies confirmed that 2 
(TED-347) binds and forms covalent adducts with TEAD4 in these cells.  Studies showing GBM43 
cells treated with 2 (TED-347) and 5 (TED-551) had significant reduced rates of proliferation 
suggests that our method to allosterically target the TEAD4•Yap1 interaction is a promising 
paradigm for the development of therapeutics to treat GBM tumor growth in vivo.  In fact, these 
compounds may also be effective against other tumors as studies have shown several 
components of the Hippo pathway to act as oncogenes in pancreatic ductal adenocarcinoma and 
breast cancer. 
In sum, the development of 2 (TED-347) and derivatives is a significant breakthrough as there 
are no existing inhibitors of the TEAD4•Yap1 interaction to enable exploration of Hippo in cell 
culture and in vivo.   Furthermore, these compounds suggest that pockets outside tight and 
challenging protein-protein interaction interfaces with nucleophilic residues may be suitable for 
the development of allosteric small-molecule inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 SIGNIFICANCE 
The Hippo pathway controls tissue homeostasis and organ size.  Hippo signaling leads to 
phosphorylation of the transcriptional co-activator Yap, which is sequestered in the cytoplasm and 
degraded.  In cancer, Yap phosphorylation is inhibited, resulting in its entry into the nucleus and 
binding to TEAD transcription factors.  TEAD activation leads to the expression of a range of 
proteins that result in cell growth, apoptotic avoidance, and stem cell self-renewal.  Here, we 
report small-molecule inhibitors of the TEAD•Yap protein-protein interaction following an 
innovative strategy that consisted of developing a compound that forms a covalent bond with a 
conserved cysteine within the palmitate binding pocket of TEADs.  This compound led to allosteric 
inhibition of the TEAD•Yap interaction.  Considering the profound interest in Hippo, these 
compounds will serve as tools to explore the role of Hippo in normal and pathological processes.   
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FIGURE LEGENDS 
Figure 1. Three-dimensional structures and free energy calculations.  (A)  Stereo view of the 
X-ray structure of the TEAD4•Yap1 complex (PDB ID: 3JUA). TEAD4 and Yap1 are shown in grey 
and cyan ribbon representation, respectively.  (B) Structure of the TEAD4•Yap1 complex 
depicting the deep hydrophobic pocket of TEAD4.  The pocket is occupied by palmitate, which is 
shown in capped-sticks and color-coded by atom type (yellow and red correspond to carbon and 
oxygen atoms, respectively).  The pocket is shown in solvent-accessible surface area and color-
coded by hydrophobicity.  (C)  Non-covalent complex of 2 (TED-347) bound to TEAD4. Compound 
2 (TED-347) and surrounding amino acids are shown in capped sticks and color-coded by atom 
type. (D) Covalent complex of 2 (TED-347) and TEAD4. Compound 2 (TED-347) and surrounding 
residues are shown in capped-sticks and color-coded by atom type. (E) Free energy calculations 
between the change in free energy of the non-covalently and covalent bound compounds with the 
apo TEAD4•Yap1 complex; mean ± s.e.; n = 30000 snapshots. (F) The change in free energy 
between non-covalently and covalent bound compounds; mean ± s.e.; n = 30000 snapshots. P 
values were calculated using two-tailed t-tests. ***P < 0.0005. 
Figure 2. Compound structures. 
Figure 3. Compounds inhibit TEAD4•Yap1 protein-protein interaction. (A) Increasing 
concentration of TEAD4 incubated with 16 nM FAM-labeled Yap (FAM-Yap60-99) peptide followed 
by measurements of changes in fluorescence polarization (mean ± s.d.; n = 3). Inset: An 
illustration of the fluorescence polarization assay, where the bound FAM-Yap60-99 is displaced 
from TEAD4 due to the interaction by an inhibitor (TED), resulting in loss of polarization. (B) 
TEAD4 was incubated with increasing concentration of compound for 24 h at 4°C followed by 
addition of FAM-Yap60-99 to measure changes in fluorescence polarization (mean ± s.d.; n = 3). 
(C) Time-dependent inhibition of TEAD4 by 2 (TED-347) was assessed by fluorescence 
polarization using FAM-Yap60-99 at 10 different concentration (0.1-100 µM) following 0.5, 6, 24 and 
48 h incubation at 4°C (mean ± s.d.; n = 3). (D) Time-dependent inhibition of TEAD4 by 2 (TED-
347) was assessed by fluorescence polarization at 10 concentrations ranging from 0.1 to 100 µM 
following incubation at 0.5, 6, 24, and 48 h at 4°C (mean ± s.d.; n = 3). The observed rate of 
inactivation (kobs) was calculated at each compound concentration using percent inhibition data 
at each time point.  The rate constant is plotted against the concentration of compound. (E) 
TEAD4 was incubated with 50 µM 2 (TED-347) for 24 h at 4°C, then dialyzed against PBS for 24 
h at 4°C, prior to addition of FAM-Yap60-99 for fluorescence polarization measurements (mean ± 
s.d.; n = 3). (F) 10 µM of TEAD4 was incubated with 200 µM compounds for 24 h at 4°C, and then 
analyzed by ESI mass spectrometry. (G) 10 µM TEAD4 was incubated with 2, 10, 50 µM 2 (TED-
347) for 0.5, 6, 25 h at 4°C and were analyzed by ESI mass spectrometry. Percent ratio of the 
adduct over total protein signal, quantified from the relative ion count, is plotted versus time. (H) 
TEAD4 is incubated with DMSO or 2 (TED-347) followed by injection into SEC column.  No 
significant aggregation is observed. 
Figure 4.  2 (TED-347) forms an adduct at Cys-367 on TEAD4. (A) 10 µM TEAD4 Cys367Ser 
mutant was incubated with 200 µM compound for 24 h at 4°C and then analyzed by ESI mass 
spectrometry. (B) Increasing concentration of TEAD4 Cys367Ser mutant was mixed with 16 nM 
FAM-Yap60-99 peptide and fluorescence polarization due to binding was measured (mean ± s.d.; 
n = 3). (C) TEAD4 Cys367Ser mutant was incubated with increasing concentration of compounds 
for 24 h at 4°C followed by addition of FAM-Yap60-99 for fluorescence polarization measurements 
(mean ± s.d.; n = 3). (D) Biotin-labeled GST-Yap1 was captured onto streptavidin-conjugated 
biolayer interferometry sensors which were dipped into varying concentrations of TEAD4. The 
binding of TEAD4 to the captured Yap is measured by biolayer interferometry (mean ± s.d.; n = 
3). (E) Biotin-labeled GST-Yap1 was captured onto streptavidin-conjugated biolayer 
interferometry sensors which were dipped into solutions containing 100 nM TEAD4, pre-incubated 
with varying concentrations of 2 (TED-347) for 24 or 48 h at 4°C (mean ± s.d.; n = 3). (F) 
Increasing concentration of HIS-TEAD2 was mixed with 16 nM FAM-Yap60-99 peptide and 
fluorescence polarization due to binding was measured (mean ± s.d.; n = 3). (G) HIS-TEAD2 was 
incubated with increasing concentration of compounds for 24 h at 4°C followed by addition of 
FAM-Yap60-99 for fluorescence polarization measurements (mean ± s.d.; n = 3). (H) Urokinase 
receptor (uPAR) was incubated with varying concentrations of compounds for 24 h at 4°C followed 
by addition of a urokinase-derived fluorescently-labeled peptide AE147 for fluorescence 
polarization measurements, according to our previously established protocol (Mani, et al., 2013) 
(mean ± s.d.; n = 3). (I) The β-3 subunit of the voltage-gated calcium channel Cav2.2 was 
incubated with varying concentrations of compounds for 24 h at 4°C followed by addition of an α-
subunit peptide that was fluorescently labeled for fluorescence polarization measurement (mean 
± s.d.; n = 3). 
Figure 5. Crystal structure of TEAD2 in complex with 2 (TED-347). (A) Stereo image of 2 
(TED-347) covalently bound to Cys-380 in the central binding pocket of TEAD2. The 2|Fo| –
 |Fc|αcalc map around 2 (TED-347) is illustrated in black mesh. Compound 2 (TED-347) and 
residues near the reaction site of 2 (TED-347) are shown in sticks (green carbon, red oxygen, 
blue nitrogen, and gold sulfur) with accompanying labels. (B) Two-dimensional ligand interaction 
map of covalently bound compound 2 (TED-347) in the central pocket of TEAD2. 
Figure 6.  Compound 2 (TED-347) inhibits TEAD transcriptional activity and protein-protein 
interactions in cell culture. (A) The activity of the TEAD4 luciferase reporter was measured in 
HEK-293 cells treated with either vehicle or compound 2 (TED-347). CNYT corresponds to no 
transfection; mean ± s.d.; n = 3 biological replicates. (B) Co-immunoprecipitation of Flag-tagged 
Yap1 and myc-tagged TEAD4 from lysates from HEK-293 cells treated with vehicle or compound 
2 (TED-347), or a peptide (FAM-Yap60-99) containing the residues in Yap1 that directly bind to 
TEAD4.  (C) Average normalized values relative to lane A from three biologic replicates; mean ± 
s.d.; n = 3 biological replicates.  (D)  Lysates from HEK-293T cells treated with 2 (TED-347) or 5 
(TED-551) were treated with 9 (TED-549) followed-up by pull-down and detection of TEAD4. 
Proteins in complexes that were retained by streptavidin pull-down were detected by immunoblot 
analysis using the indicated antibody.  (E) Average normalized values relative to lane A from three 
biological replicates; mean ± s.d.; n = 3 biological replicates.  (F) qRT-PCR analysis of CTGF 
levels following treatment of HEK-293T cells with compounds for 48 h; mean ± s.d.; n = 3 
biological replicates.  P values were calculated using two-tailed t-tests. *P < 0.05, **P < 0.005, 
***P < 0.0005.   
Figure 7.  Compound 2 (TED-347) inhibits patient-derived GBM43 glioblastoma growth in 
3D spheroids.  (A)  Spheroids of patient-derived GBM43 glioblastoma cell lines were grown and 
treated with 1 (TED-346), 2 (TED-347), and 5 (TED-551); mean ± s.d.; n = 3 biological replicates.  
(B)  The activity of the TEAD4 luciferase reporter was measured in GBM43 cells treated with 
either vehicle or compound 2 (TED-347). CNYT corresponds to no transfection; mean ± s.d.; n = 
3 biological replicates. (C)  qRT-PCR analysis of CTGF levels following treatment of HEK-293T 
cells with compounds; mean ± s.d.; n = 3 biological replicates.  (D) Spheroids of patient-derived 
GBM43 glioblastoma cell lines were grown and treated with temozolomide; mean± s.d. of 
biological replicates (n = 3). P values were calculated using two-tailed t-tests. *P < 0.05, **P < 
0.005, ***P < 0.0005. 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Monoclonal Anti-c-Myc antibody produced in mouse Fisher Cat# MA1980 
   
   
   
   
Bacterial and Virus Strains  
E. coli BL-21 (DE3) New England Biolabs Cat# C2527H 
   
   
   
Biological Samples   
   
   
   
   
   
Chemicals, Peptides, and Recombinant Proteins 
HRV-3C protease ThermoFisher Cat# 88946 
Thrombin Sepharose Beads BioVision Cat# 7925 
FAM-Yap(60-99) peptide: FAM- 
DSETDLEALFNAVMNPKTANVPQTVPMCLRKLPASFC
KPP 
Synthesized by 
American Peptide N/A 
Recombinant Protein: GST-TEAD4 (aa 217-434; ref# 
NP_003204.3) This study N/A 
Recombinant Protein: GST-TEAD4 C367S (217-434) This study N/A 
Recombinant Protein: GST-YAP1 (ref# 
NP_001123617.1) This study  N/A 
Recombinant Protein: HIS-TEAD2 (aa 217-447; ref# 
NP_003589.1) This study N/A 
Fetal Bovine Serum- Premium  Atlanta Biologicals Cat# S11150 
DMEM (Dulbecco’s Modified Eagle Medium), high 
glucose  
Gibco Cat# 11965-092 
DMEM/F12 1:1 Gibco Cat# 11320-033 
B-27TM Supplement (50X), minus vitamin A  Gibco Cat# 12587-010  
Animal-Free Recombinant Human EGF  Peprotech Cat# AF-100-15 
Animal-Free Recombinant Human FGF-basic Peprotech  Cat# AF-100-18B 
alamarBlueTM Cell Viability Reagent  Invitrogen Cat# DAL1100 
DNA fingerprint analysis  IDEXX BioResearch N/A 
   
Critical Commercial Assays 
Dual-Glo Luciferase Assay System Promega Cat# E2920 
GenJet Plus DNA In Vitro Tranfection Reagent SignaGen Cat# SL100499 
   
Deposited Data 
Crystal structure of human TEAD2-Yap binding domain 
covalently bound to 2 This paper PDB: 6E5G 
Crystal structure of the palmitoylated human TEAD2 
transcription factor 
Noland C. L. et al. 
Structure 24, 179-186 
(2016). 
PDB: 5EMV 
Structural basis of YAP recognition by TEAD4 in the 
Hippo pathway 
Chen L. et al. Genes 
Dev. 24, 290-300 
(2010). 
PDB: 3JUA 
Crystal structure of human transcription factor TEAD2 in 
complex with palmitate 
Chan P. et al. Nat. 
Chem. Biol. 12, 282-
289 (2016). 
PDB: 5HGU 
Crystal structure of human transcription factor TEAD2 in 
complex with flufenamic acid 
Pobbati A. V. et al. 
Structure 23, 2076-
2086 (2015). 
PDB: 5DQ8 
Experimental Models: Cell Lines 
HEK-293 
ATCC 
Cat# CRL-1573; sex 
of cell line is not 
available. 
GBM43 Mayo Clinic 
Gift from Dr. Jann 
Sarkaria; cells were 
obtained from male 
patient. 
Experimental Models: Organisms/Strains 
   
   
   
   
   
   
Oligonucleotides 
CTGF Forward Primer-5’TTGGCCCAGACCCAACTA3′ This study N/A 
CTGF Reverse Primer- 5’GCAGGAGGCGTTGTCATT3’ This study N/A 
ß-actin Forward Primer-5’TTGGCAATGAGCGGTTCC3’ This study N/A 
ß-actin Reverse Primer-
5’GTTGAAGGTAGTTTCGTGGATG3’ This study N/A 
   
Recombinant DNA 
Plasmid: pGEX-6P-1 TEAD4 (217-434) This study N/A 
Plasmid: pGEX-6P-1 TEAD4 (217-434) C367S This study N/A 
Plasmid: pGEX-6P-1 Yap1 This study N/A 
Plasmid: pET-28a TEAD2 (217-447) This study N/A 
   
   
   
Software and Algorithms 
XDS 
Kabsch, W. Acta 
Cryst. D66, 125-132 
(2010) 
http://xds.mpimf-
heidelberg.mpg.de 
RRID:SCR_015652 
PHENIX 
Adams, P. D. et al. 
Acta Cryst. D66, 213-
221 (2010). 
http://www.phenix-
online.org 
RRID:SCR_014224 
PHASER 
McCoy, A. J. et al. J. 
Appl. Cryst. 40, 658-
674 (2007). 
http://www.phaser.ci
mr.cam.ac.uk 
RRID:SCR_014219 
Coot 
Emsley, P. et al. Acta 
Cryst. D66, 486-501 
(2010). 
http://www2.mrc-
lmb.cam.ac.uk/Perso
nal/pemsley/coot/ 
RRID:SCR_014222 
PyMOL v2.0.6 PyMOL by 
Schrödinger 
https://pymol.org 
Small-Molecule Drug Discovery Suite v2017-4 Schrödinger https://www.schrodin
ger.com/suites/small
-molecule-drug-
discovery-suite 
Amber14 (Serial/GPU) The Amber Project http://ambermd.org/
AmberMD.php 
AmberTools16 (MPI/CPU) The Amber Project http://ambermd.org/
AmberTools.php 
Gaussian 09 Gaussian, Inc http://gaussian.com/ 
SigmaPlot 13.0 Systat Software, Inc https://systatsoftwar
e.com/products/sigm
aplot/ 
   
   
Other 
GSTrap FF column GE Life Science Cat# 17513101 
HisTrap FF column GE Life Science Cat# 17525501 
HiLoad 26/600 Superdex 200 pg SEC column GE Life Science Cat# 28989336 
Envision Multilabel Plate Reader PerkinElmer Cat# 2102 
Agilent 6520 Accurate Mass Q-TOF Agilent Cat# 6520 
Agilent 1200 LC-MS Agilent Cat# 1200 
OctetRed 384  ForteBio Cat# RED384 
96-well Clear Flat Bottom Ultra-Low Attachment 
Microplate 
Corning Cat# 3474 
 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Samy O. Meroueh (smeroueh@iu.edu). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
HEK-293 and GBM43 cells were cultured in DMEM medium with glutamine (Cellgro, Manassas, 
VA) supplemented with 10 % FBS and 1 % penicillin/streptomycin in 5 % CO2 at 37 °C. 
E. coli BL-21 (DE3) strain was purchased from New England Biolabs (Ipswich, MA) and cultured 
and grown in Luria Broth media at 37 °C. 
 
METHOD DETAILS 
 
Luciferase reporter assay   
HEK-293 cells plated at 2.4×104 cells/well in a 96-well microplate were transfected after 24 hours 
with the a pGL3.1 reporter containing the CTGF promoter and a plasmid encoding TK-Renilla 
luciferase in combination with control vectors or vectors that express Yap1 and TEAD4. After 48 
h cells, were treated with 0.5, 1.0, 5.0 or 10 µM of 2 (TED-347) for another 48 h. Luciferase activity 
was measured according to the Dual-Glo luciferase assay (Promega) instructions using a Biotek 
Synergy Neo2 plate reader. Relative luciferase activity represents the ratio of firefly/renilla 
luminescence values.  
Covalent Pull Down of TEAD4 
HEK293 cells transfected with the myc-TEAD4 construct were grown for 48 h and then treated 
with DMSO or with 25 µM of 2 (TED-347) for an additional 48 h. Cells were then harvested in lysis 
buffer (50 mM Tris-HCl, pH 7.3, 150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100, PhosSTOP 
phosphatase inhibitor cocktail, and EDTA-free protease inhibitors cocktail). Cell lysates 
containing 2 mg of protein were incubated with the indicated compounds or DMSO for 24 h. 
Extracts were then incubated with Dynabeads M-280 Streptavidin (Sigma-Aldrich) for 2 h at 4 °C. 
The Dynabeads were then washed and bound proteins were denatured and eluted according to 
the manufacturer’s instructions. Relative levels of myc-TEAD4 from each complex were measured 
by immunoblot analysis with the anti-c-Myc antibody (1:5,000, Sigma-Aldrich). 
Co-immunoprecipitation  
HEK293 cells transfected with Flag-YAP1 alone or in combination with myc-TEAD4 were 
incubated with DMSO or the indicated amount of compounds for 48 hours. Cells were harvested 
in lysis buffer (50 mM Tris-HCl, pH 7.3, 150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100, 
PhosSTOP phosphatase inhibitor cocktail, and complete EDTA-free protease inhibitors cocktail). 
Extracts were immunoprecipitated with magnetic beads coupled to the M2 (anti-Flag) antibody 
(Sigma-Aldrich) for 4 h at 4 °C. The Dynabeads were then washed and bound proteins were 
denatured and eluted according to the manufacturer’s instructions. Relative levels of myc-TEAD4 
from each complex was then measured by immunoblot analysis with the anti-c-Myc antibody 
(1:5,000, Sigma-Aldrich). 
RNA extraction and real-time PCR  
HEK293 cells co-transfected the Flag-YAP and myc-TEAD4 constructs were incubated with 
DMSO or the indicated amount of compounds for 48 h. Total RNA was purified using the RNeasy 
plus mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. 
Complementary DNA was synthesized from 500 ng total RNA with Oligo-dT primers and the Multi-
Scribe reverse transcriptase (Fisher, Waltham, MA) according to the manufacturer’s instructions.   
Real-time PCR reactions utilized 100 ng cDNA, 200 nM gene specific primers and the Sensifast 
No-ROX mix (Bioline, Taunton, MA) in a total volume of 20 ul. All measurements were carried out 
in triplicate using an Eppendorf Mastercycler® RealPlex2. The sequences of primers for CTGF 
were forward, 5 ′ - TTGGCCCAGACCCAACTA-3; and reverse, 5 ′ - 
GCAGGAGGCGTTGTCATT-3’. The primer sequences for β -actin were forward, 5 ′ -
TTGGCAATGAGCGGTTCC-3; and reverse, 5′- GTTGAAGGTAGTTTCGTGGATG-3′. 
Sphere-Forming Assay  
Sphere-Forming Assay. The GBM43 xenograft tissue was a kind gift from Dr. Jann Sarkaria (Mayo 
Clinic, Rochester, IN), and tumors were expanded by passage in the flank of NOD/SCIDnull 
mice. To generate GBM43 cell lines, tumors were harvested, disaggregated, and maintained in 
2.5% FBS for 14 days on Matrigel-coated plates (BD Biosciences) to remove murine fibroblasts. 
In-vitro GBM43 cell lines were propagated in DMEM with 10% FBS for no more than 7 passages. 
Cell line identity was confirmed by DNA fingerprint analysis (IDEXX BioResearch) for species and 
baseline short-tandem repeat analysis testing. GBM43 spheroids were generated by plating early-
passage cells at 2.5 x 104 cells per well in 96-well ultralow attachment plates (Corning Inc.) in 
DMEM/F12 (1:1; GIBCO) supplemented with 2% B27 supplement (GIBCO), 20 ng/mL epidermal 
growth factor (EGF), and 20 ng/mL fibroblast growth factor (FGF) (Peprotech) for 2 days.  The 
spheroids were then treated with compounds 1 (TED-346), 2 (TED-347) and 5 (TED-551) and 
growth analyzed by Alamar blue staining. 
Protein Expression and Purification   
TEAD4 (217-434), TEAD4 (217-434) Cys367Ser mutant and Yap1 (Full-length) were expressed 
as GST-fusion proteins in BL-21 (DE3) strain of E. coli from the pGEX-6P-1 vector. Transformed 
bacteria were grown in LB at 37 °C until they reached an OD600 of 0.6 – 0.8.  Isopropyl-β-D-
galactoside (IPTG) was added to a final concentration of 0.5 mM and cells were then incubated 
at 16 °C for 16 h. Cell pellets were re-suspended in a buffer containing 200 mM NaCl, 20 mM 
Tris, 2 mM dithiothreitol (DTT), pH 8.0, and lysed by passage through a microfluidizer. Cell debris 
was removed by centrifugation at 35,000 x g for 1 h. Clarified lysates were loaded onto a pre-
equilibrated 5 mL GSTrap HP column at 1 ml/min. The column was washed with 5 column 
volumes of buffer and the protein was eluted with 10 mM reduced glutathione in the same buffer. 
The protein was further purified on a HiLoad 26/600 Superdex 200 pg SEC column (GE, Boston, 
MA) with 100 mM NaCl, 20 mM Tris, 2 mM DTT, pH 8.0 as buffer. The GST-tag was cleaved from 
proteins by incubation with the HRV-3C protease (ThermoFisher, Waltham, MA) at 100:1 w/w 
ratio while dialyzing against PBS with 5 mM β-mercaptoethanol for 48 h at 4 °C. The cleavage 
solution was passed through a GSTrap HP column to remove the cleaved GST and the HRV-3C 
protease. Cleavage was verified by SDS-PAGE and mass spectrometry. 
TEAD2 (217-447) was expressed as N-terminal HIS-fusion protein in BL-21 (DE3) strain of E. coli 
from the pET-28a vector. Transformed bacteria were grown in Terrific Broth at 37 °C until they 
reached an OD600 of 0.6 – 0.8.  IPTG was added to a final concentration of 0.5 mM and cells were 
then incubated at 16 °C for 16 h. Cell pellets were re-suspended in a buffer containing 500 mM 
NaCl, 50 mM HEPES, 8 mM β-mercaptoethanol, pH 7.5 and lysed by multiple passages through 
a microfluidizer. Cell debris was removed by centrifugation at 35,000 x g for 1 h. Clarified lysates 
were loaded onto a pre-equilibrated 5 mL HisTrap FF column at 1 mL/min. The column was 
washed with 100 mL of buffer containing 300 mM NaCl, 25 mM HEPES, 1 mM TCEP, 5 % v/v 
glycerol, 30 mM imidazole, pH 7.5 prior to elution with the same buffer containing 300 mM 
imidazole. The protein was further purified on a HiLoad 26/600 Superdex 200 pg SEC column 
(GE, Boston, MA) with 150 mM NaCl, 25 mM HEPES, 1 mM TCEP, pH 7.5 as buffer. For 
crystallization trials, the elution from the HisTrapFF affinity chromatography was dialyzed against 
150 mM NaCl, 50 mM Tris pH 8.0 for 2 h, then cleaved with 1:100 w/w thrombin at 4 °C overnight. 
The cleaved protein was dialyzed against 300 mM NaCl, 25 mM HEPES, 1 mM TCEP, 5 % v/v 
glycerol, 10 mM imidazole, pH 7.5. The cleaved HIS-tag was removed by passing through the 
HisTrap FF column. TEAD2 without the HIS-tag was further purified on SEC, as above. 
Size-Exclusion Chromatography  
2 ml of 6.3 µM GST-TEAD4 in PBS was incubated with 100 µM 2 (TED-347) in 2 % v/v DMSO or 
DMSO without compound for 24 h at 4 °C. After the incubation, the samples were injected into a 
HiLoad 26/600 Superdex 200 pg SEC column, pre-equilibrated with PBS. The elution profile of 
the column was analyzed for protein aggregation. 
Fluorescence Polarization  
GST-TEAD4, GST-TEAD4 Cys367Ser mutant or HIS-TEAD2 interaction with Yap1 was 
investigated using a fluorescently-labeled peptide (FAM-Yap60-99), consisting of FAM-labeled 
TEAD-binding peptide fragment of Yap1 (FAM-
DSETDLEALFNAVMNPKTANVPQTVPMCLRKLPASFCKPP), which has a disulfide bridge 
(American Peptide, Sunnyvale, CA).   Addition of FAM-Yap60-99 to the TEAD was followed by 
measurement of changes in polarization.  40 µL of 125 nM GST-TEAD4 WT or GST-TEAD4 
Cys367Ser in assay buffer (PBS with 0.01 % v/v Triton-X100) or 40 µL of 64 nM HIS-TEAD2 was 
added to a 384-well black polystyrene plate (Cat. No. 262260; Nunc, Roskilde, Denmark) and 
incubated with 5 µL of 2 – 2000 µM serially diluted compounds in assay buffer supplemented with 
20 % v/v DMSO for 24 h at 4 °C. Finally, 5 µL of 160 nM FAM-Yap60-99 peptide was added, the 
plate centrifuged, and the polarization was measured on an Envision Multilabel Plate Reader 
(PerkinElmer, Waltham, MA) using a filter set with excitation and emission wavelengths of 485 
and 535 nm, respectively. Percent inhibition was calculated as relative to a minimum inhibition 
control, which is without compound, and a maximum inhibition control, which is without a TEAD.  
For the determination of the inhibition efficiency kinact/KI, the protein – compound incubation time 
was varied between 0.5 – 48 h, prior to the addition of the FAM-Yap60-99 peptide and fluorescence 
polarization measurements. The progressive decrease in TEAD activities were plotted against 
time for all 10 concentrations (0.2 – 100 µM) of the compounds and the observed rate of inhibition 
(kobs) was calculated by fitting a simple exponential function. The observed rate of inhibition was 
then plotted against the concentration of the compound and a polynomial function 𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜 = 𝑘𝑘𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 [𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖]
𝐾𝐾𝐼𝐼+ [𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖]  was fitted to determine the kinact and KI values. 
Crystallization of TEAD2 and Structure Refinement  
Purified TEAD2 was concentrated to ~12 mg/mL and crystallized at 20°C using the hanging-drop 
vapor-diffusion method with a reservoir solution containing 0.1 M HEPES (pH 7.2 – 7.4) and 2.4 
- 2.8 M sodium formate. The crystals were soaked in reservoir solution supplemented with 3 - 5 
mM of 2 (TED-347) and 25 % v/v glycerol for 3 h and were subsequently flash-cooled in liquid 
nitrogen. To rule out the possibility that the observed density of 2 (TED-347) was not the 
endogenous S-palmitoylation from protein expression (Noland, et al., 2016), some crystals were 
soaked in a cryo-protectant solution supplemented with 2 mM DTT for 2 h to soak out the fatty 
acid. The crystal structure of these crystals was solved and no extra electron-density was 
observed. Another batch of crystals were soaked in three steps: 1)- in a cryo-protectant solution 
supplemented with 2 mM DTT for 2 h, 2)- in a cryo-protectant solution (wash) for 2 h and 3)- in a 
cryo-protectant solution supplemented with 3-5 mM of 2 (TED-347) for 3 h. 
Data was collected at beamline 4.2.2 at the Advanced Light Source (ALS, Berkeley, CA, USA) 
and processed with XDS. All crystals contained two molecules per asymmetric unit and the 
symmetry corresponded to space group C2. Molecular Replacement was used to obtain the initial 
phases using Phaser and the crystal structure of TEAD2 transcriptional activation domain (PDB 
5EMV) as the search model. Initial model building was carried out using Autobuild in PHENIX. 
The final model (Rfree 0.268, with good geometry and no Ramachandran outliers) was obtained 
by iterative cycles of manual building in Coot and refinements with PHENIX-refine. 
Protein Mass Spectrometry   
Compounds at 200 µM concentrations (unless otherwise specified) were incubated with 10 µM 
TEAD4 WT or TEAD4 Cys367Ser mutant in 20 mM NH4OAc for 24 h (unless otherwise specified) 
at 4 °C. The samples were centrifuged at 20,000 x g for 20 min to remove precipitants prior to 
being injected into an empty column on an Agilent 1200 liquid chromatography system (Agilent, 
Santa Clara, CA), using 80 % Buffer A (H2O, 5 mM NH4OAc) and 20 % Buffer B (ACN, 5 mM 
NH4OAc), and the masses were detected on an Agilent 6520 Accurate Mass Q-TOF.  
Biolayer Interferometry  
Biolayer Interferometry was measured on OctetRed 384 (ForteBio, Menlo Park, CA) using PBS 
with 0.025% v/v Tween-20 at 30 °C with constant shaking at 1000 rpm. Streptavidin-conjugated 
sensors (ForteBio, Menlo Park, CA) were loaded with 30 µg/ml biotin-labeled GST-Yap or biocytin 
and were introduced to 1-1000 nM TEAD4. The sensors were regenerated with 5 mM HCl solution 
after each interaction. For compound inhibition study, 100 nM TEAD4 was pre-incubated with 0.1 
– 100 µM 2 (TED-347) in 2 % v/v DMSO for 24 h at 4 °C prior to interaction with captured GST-
Yap.  
In silico Protein Preparation  
The crystal structures of TEAD4•YAP (PDB ID: 3JUA), TEAD2•PLM (PDB ID: 5HGU, palmitic 
acid), and TEAD2•FLF (PDB ID: 5DQ8, flufenamic acid) were retrieved and prepared using the 
Protein Preparation Wizard in the Schrödinger software package (Schrödinger LLC, New York, 
NY, 2017)(Greenwood, et al., 2010; Sastry, et al., 2013). Bond orders were assigned and 
hydrogen atoms were added. Missing side chains and loops were introduced using the Prime 
module(Jacobson, et al., 2004). The resulting protein and compound structures were protonated 
at pH 7.0 using PROPKA (Olsson, et al., 2011) and Epik (Shelley, et al., 2007), respectively. The 
structure of 2 (TED-347) was generated by replacing the acetic acid on FLF with chloromethyl 
ketone. Subsequently, the binding modes of PLP and 2 (TED-347) to TEAD4 were obtained using 
the align function in PyMOL (Schrodinger, 2015). 
Covalent Docking  
The covalent structure of TEAD4•2 was generated using CovDock (Toledo Warshaviak, et al., 
2014). The chloromethyl ketone group of 2 was defined as the reaction group for a nucleophilic 
substitution reaction with the TEAD4 Cys-360. Residues within 3.0 Å of 2 were refined during 
covalent docking. The covalent bond parameters from the OPLS force field (Banks, et al., 2005) 
were extracted. 
Molecular Dynamics Simulations  
The structures of TEAD4•Yap1, TEAD4•Yap1•PLM, non-covalent [TEAD4•2]•Yap1, and covalent 
[TEAD4-2]•Yap1 were used to run molecular dynamics simulations using the AMBER14 software 
package (Case, et al., 2015). The restrained electrostatic potential (RESP) atomic charges (Aduri, 
et al., 2007) of PLM, 2 in the covalent and non-covalent complexes were calculated at the HF/6-
31G* level (McWeeny and Diercksen, 1968; Petersson, et al., 1988; Pople and Nesbet, 1954) 
using the Gaussian 09 package (Frisch, et al., 2009). In the covalent [TEAD4-2]•Yap1 complex, 
2, Leu-359, Cys-360, and Glu-361 were extracted for RESP charge fitting. The atom charges of 
Cys-360 were replaced by RESP charges and the optimized parameters of bond length, bond 
angle, and dihedral angle between Cys-360 and 2 were used to build new frcmod parameters. 
The α-carbon atom of 2 and sulfur atom of Cys-360 were bonded using tleap program.  
 Complexes were immersed in a box of TIP3P water molecules (Jorgensen, et al., 1983). 
No atom on the complex was within 14 Å of any side of the box. The solvated box was further 
neutralized with Na+ or Cl- counterions using the tleap program. Simulations were carried out 
using the GPU accelerated version of the pmemd program with ff14SB (Maier, et al., 2015) and 
gaff force fields (Wang, et al., 2004) in periodic boundary conditions. All bonds involving hydrogen 
atoms were constrained by using the SHAKE algorithm (Ryckaert, et al., 1977), and a 2 
femtoseconds (fs) time step was used in the simulation. The particle mesh Ewald (PME) method 
(Darden, et al., 1993) was used to treat long-range electrostatics. Simulations were run at 298 K 
under 1 atm in NPT ensemble employing Langevin thermostat and Berendsen barostat. Water 
molecules were first energy-minimized and equilibrated by running a short simulation with the 
complex fixed using Cartesian restraints. A series of energy minimizations were subsequently 
applied in which the Cartesian restraints were gradually relaxed from 500 kcal∙Å-2 to 0 kcal∙Å-2, 
and the system was subsequently gradually heated to 298 K with a 48 ps molecular dynamics 
run. For each complex, we generated 50 independent simulations (replicates) that are each 50 
ns in length. The initial velocity of each replicate was randomly assigned. In total, 2.5 µs of 
simulation was run for each complex.  
Free Energy Calculations  
In each of the 50 trajectories (50 ns in length), the first 2 ns were discarded for equilibration. 
Snapshots were saved every 1 ps, yielding 48000 structures per trajectory. 30000 snapshots 
were selected at regular intervals for free energy calculations using the cpptraj program (Roe and 
Cheatham, 2013). The Molecular Mechanics-Generalized Born Surface Area (MM-GBSA)(Still, 
et al., 1990) method was used to calculate the free energy using the MMPBSA.py script (Miller, 
et al., 2012). The calculation using the GB method was performed with sander and Onufriev’s GB 
model (Feig, et al., 2004; Onufriev, et al., 2004). Solvent-accessible surface area (SASA) 
calculations were switched to the icosahedron (ICOSA) method, where surface areas are 
computed by recursively approximating a sphere around an atom, starting from an icosahedron. 
Salt concentration was set to 0.1 M. The entropy was determined by normal mode calculations 
(Brooks and Karplus, 1983) with the mmpbsa_py_nabnmode module by selecting 150 of the 
30000 snapshots used in the free energy calculations at regular intervals. The maximum number 
of cycles of minimization was set to 10000. The convergence criterion for the energy gradient to 
stop minimization was 0.5. In total, 30000 frames were used for each MM-GBSA calculations 
while 150 frames were used for each normal mode analysis. All other parameters were left at 
default values. 
 The MM-GBSA binding free energy is expressed as: 
∆GMM-GBSA = ∆EGBTOT − T∆SNMODE 
where ∆EGBTOT is the combined internal and solvation energies, T is the temperature (298.15 K). 
∆SNMODE is the entropy determined by normal mode calculations. The total enthalpy from the 
generalized Born model, ∆EGBTOT, is the sum of 4 components: 
∆EGBTOT = ∆EVDW + ∆EELE + ∆EGB + ∆ESURF 
where ∆EVDW and ∆EELE are the van der Waals and electrostatic energies, respectively, and ∆EGB 
and ∆ESURF are the polar and non-polar desolvation energies, respectively. All binding energies 
are determined by: 
∆E = ECOM - EREC - ELIG 
where ECOM, EREC and ELIG are total energies corresponding to the complex, receptor, and ligand, 
respectively. The relative difference in free energy is determined by: 
∆∆G = ∆GCOM - ∆GAPO 
where ∆GCOM and ∆GAPO are the covalent or non-covalent complex and the unbound native apo 
complex, respectively. 
 
Synthesis   
All chemicals were purchased from either Aldrich or Acros and used as received.  Column 
chromatography was carried out with silica gel (25-63 µ).  Mass spectra were measured on an 
Agilent 6520 Accurate Mass Q-TOF instrument.  1H NMR spectra were recorded in CDCl3 or 
Methanol-d4 on a Bruker 500 MHz spectrometer.  Chemical shifts are reported using residual 
CHCl3 or MeOH as internal references. All compounds that were evaluated in biological assays 
had >95% purity by HPLC.  
 
2-((3-(trifluoromethyl)phenyl)amino)benzoic acid (1, TED-346). 
Purchased from a commercial source. 
F3C
H
N
OHO
1 (TED-346)  
1H NMR (400 MHz, CDCl3): δ 9.42 (s, 1H), 8.09-8.07 (dd, J=8.0Hz, J=1.2Hz, 1H), 7.51 (s, 1H), 
7.49-7.40 (m, 3H), 7.36-7.34 (m, 1H), 7.27-7.25 (m, 2H), 6.87-6.83 (t, J=8.0Hz, 1H). 
 
Synthesis of 2-chloro-1-(2-((3-(trifluoromethyl)phenyl)amino)phenyl) ethanone (2, TED-
347). 
 
H
N
O
Cl
F3C
H
N
O OH
F3C
N2 TMS
Conc.HCl
2 (TED-347)1 (TED-346)  
A solution of 2-((3-(trifluoromethyl)phenyl)amino)benzoic acid (1, 200 mg, 0.71 mmol) in SOCl2 
(6 mL) was refluxed for 1h. The mixture was evaporated to dryness. The residue was dissolved 
in MeCN (10 mL) and cooled to 0 oC, followed by the addition of TMSCHN2 (1.07 mmol, 0.5 
mL). It was stirred for 1 h, and conc. HCl (0.5 mL) was added to the mixture at 0 oC.  The 
mixture was stirred for 0.5 h. The mixture was quenched with NaHCO3 (aq) and diluted with 
water. The mixture was extracted with EA (15 mL x 2). The combined organic layers were dried 
with Na2SO4, filtered and concentrated. The residue was purified by Prep-TLC (PE / EA = 5 / 1) 
to give 2-chloro-1-(2-((3-(trifluoromethyl)phenyl)amino)phenyl)ethanone (6.4 mg, 2.8%); 1H 
NMR (400 MHz, CDCl3): δ 10.43 (s, 1H), 7.79-7.64 (dd, J=4.0Hz, J=0.8Hz, 1H), 7.51-7.47 (m, 
1H), 7.45-7.41 (m, 1H), 7.38-7.36 (m, 3H), 7.29-7.26 (m, 1H), 6.85-6.82 (m, 1H), 4.75 (s, 1H); 
13C NMR (400 MHz, CDCl3) δ 193.41, 147.80, 140.67, 135.66, 132.16, 131.86, 130.04, 125.86, 
125.20, 122.49, 120.71, 120.67, 120.63, 119.33, 119.30, 119.26, 117.84, 116.87, 114.65, 46.53. 
LRMS calculated for C15H12ClF3NO + [M+H]+, 314.05 found 314.0. 
 
Synthesis of 1-(2-((3-(trifluoromethyl)phenyl)amino)phenyl)propan-1-one (3, TED-550) 
H
N
O N
F
F
F
O
H
N
O
F
F
FEtMgBr
3 (TED-550)  
To a solution of N-methoxy-N-methyl-2-((3-(trifluoromethyl)phenyl)amino)benzamide (100 mg, 
0.31 mmol) in THF (5 mL)  was added 1 M EtMgBr in THF (1.8 mL) at -78 oC under N2. The 
resulting mixture was warmed to rt and stirred for 5 h. The reaction mixture was quenched with 
sat. NH4Cl (20 mL), and extracted with EA (5 mL x 3). The organic phase was washed with 
brine, dried over Na2SO4, and filtered. The filtrate was concentrated. The residue was purified 
by prep-TLC (PE/EA=20/1) to give 1-(2-((3-(trifluoromethyl)phenyl)amino)phenyl)propan-1-one 
(15 mg, 16.5%); 1H NMR (400MHz, CDCl3): δ 10.68 (s, 1H), 7.89 (d, J=8.0Hz, 1H), 7.51 (s, 1H), 
7.30-7.46 (m, 5H), 6.83 (t, J=7.2Hz, 1H), 3.07 (q, 2H), 1.24 (t, J=7.2Hz, 3H); 13C NMR (400 
MHz, CDCl3) δ 204.20, 146.57, 141.44, 134.38, 131.59, 129.87, 125.03, 119.78, 119.72, 
118.52, 118.49, 117.79, 114.56, 32.70, 8.69. LRMS calculated for C16H15F3NO+ [M+H]+, 293.3 
found 294.1.   
  
Synthesis Scheme of 4 (TED-548) 
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Synthesis of 1-(2-((3-(2-methoxyethoxy)phenyl)amino)phenyl)ethanone (TED-548-2). 
A mixture of 3-(2-methoxyethoxy)aniline (500 mg, 2.99 mmol), 1-(2-bromophenyl)ethanone (625 
mg, 3.14 mmol), Pd2(dba)3 (275 mg, 0.30 mmol) , xphos (286 mg, 0.60 mmol), and Cs2CO3 
(1.47 g, 4.50 mmol) in dioxane (10 mL) was heated to 90 oC under N2, and stirred for 2 h. The 
reaction mixture was cooled to room temperature, and filtered over Celite. The filtrate was 
concentrated. The residue was dissolved in EA (40 mL), washed with brine, and dried over 
Na2SO4. The solution was filtered, and the filtrate was concentrated. The residue was purified 
by column chromatography (PE-PE/EA=5/1) to give 1-(2-((3-(2-
methoxyethoxy)phenyl)amino)phenyl)ethanone (710 mg, 83.2%); 1H NMR (400MHz, CDCl3): δ 
10.51 (s, 1H), 7.81 (d, J=8.0Hz, 1H), 7.30-7.31 (m, 2H), 7.23 (t, J=8.0Hz, 1H), 6.84-6.85 (m, 
2H), 6.68-6.76 (m, 2H), 4.11 (t, J=4.8Hz, 2H), 3.75 (t, J=4.8Hz, 2H), 3.45 (s, 3H), 2.64 (s, 3H). 
LRMS calculated for C17H20NO3+ [M+H]+, 286.3 found 286.2. 
Synthesis of 2-chloro-1-(2-((3-(2-methoxyethoxy)phenyl)amino)phenyl) ethanone (4, TED-
548). 
To a mixture of 1-(2-((3-(2-methoxyethoxy)phenyl)amino)phenyl)ethanone (50 mg, 0.18 mmol) 
in DCM (3 mL) were added DIEA (67 mg, 0.52 mmol) and TMSOTf (58 mg, 0.26 mmol) at 0 oC 
under N2. The resulting mixture was warmed to room temperature and stirred for 5 h. NCS (24 
mg, 0.18 mmol) was added and the mixture was stirred for another 2 h. It was quenched with 
water (10 mL), and the mixture was extracted with DCM (5mL x 3). The organic phase was 
washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated. The residue 
was purified by prep. TLC (PE/EA=5/1) to give 2-chloro-1-(2-((3-(2-
methoxyethoxy)phenyl)amino)phenyl)ethanone (5.1 mg, 8.9%); 1H NMR (400MHz, CDCl3): δ 
10.35 (s, 1H), 7.77 (d, J=8.0Hz, 1H), 7.22-7.39 (m, 4H), 7.07 (d, J=2.8Hz, 1H), 6.84 (t, J=7.2Hz, 
1H), 6.63-6.65 (m, 1H), 4.76 (s, 2H), 4.08 (t, J=4.8Hz, 2H) , 3.74 (t, J=4.8Hz, 2H) , 3.45 (s, 3H); 
13C NMR (400 MHz, CDCl3): δ 193.13, 157.99, 147.15, 137.90, 135.36, 131.25, 130.56, 117.91, 
117.49, 115.51, 110.85, 109.43, 70.95, 67.75, 59.25, 46.55. LRMS calculated for C17H19ClNO3+ 
[M+H]+, 320.8 found 320.0. 
 Synthesis Scheme of 5 (TED-551)  
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Synthesis of 1-(3-((3-(trifluoromethyl)phenyl)amino)pyridin-2-yl)ethanone (TED-551-1). 
A mixture of 1-(3-bromopyridin-2-yl)ethanone  (200 mg, 1.00 mmol), 3-(trifluoromethyl)aniline 
(161 mg, 1.00 mmol), Pd2(dba)3 (92 mg, 0.10 mmol), xphos (95 mg, 0.20 mmol), and Cs2CO3 
(489 mg, 1.50 mmol) in dioxane (10 mL) was heated to 90 oC under N2. The mixture was stirred 
for 2h. The reaction mixture was cooled to room temperature, and filtered through Celite. The 
filtrate was concentrated. The residue was dissolved in EA (40 mL), and the mixture was 
washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated. The residue 
was purified by column chromatography (PE-PE/EA=20/1) to give 1-(3-((3-
(trifluoromethyl)phenyl)amino)pyridin-2-yl)ethanone (160 mg, 57.1%); 1H NMR (400MHz, 
CDCl3): δ 10.43 (s, 1H), 8.13 (d, J=4.0Hz, 1H), 7.59 (d, J=8.0Hz, 1H), 7.47-7.51 (m, 2H), 7.39 (t, 
J=6.4Hz, 2H), 7.26-7.30 (m, 1H), 2.79 (s, 3H). LRMS calculated for C14H12F3N2O+ [M+H]+, 281.3 
found 281.1. 
 
  
Synthesis of 2-chloro-1-(3-((3-(trifluoromethyl)phenyl)amino)pyridin-2-yl)ethanone (5, 
TED-551). 
The procedure was the same as 4 (TED-548) to give 5 (TED-551). 
5 (TED-551): 1H NMR (400MHz, CDCl3): δ 10.21 (s, 1H), 8.11-8.10 (dd, J=4.0Hz, J=1.2Hz, 1H), 
7.61-7.58 (m, 1H), 7.53-7.49 (m, 2H), 7.44-7.39 (m, 2H), 7.34-7.31 (m, 1H), 5.20 (s, 2H). 13C 
NMR (400 MHz, CDCl3): δ 195.58, 143.74, 139.61, 139.07, 133.56, 132.42, 132.10, 130.32, 
129.07, 126.07, 125.05, 122.34, 121.64, 121.47, 121.39, 119.51, 119.47, 48.03. LRMS 
calculated for C14H11ClF3N2O+ [M+H]+, 315.04 found 315.0.  
 
Synthesis Scheme of 6 (TED-589) 
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Synthesis of methyl 4-methoxy-2-((3-(trifluoromethyl)phenyl)amino)benzoate (TED-589-1). 
A mixture of methyl 2-amino-4-methoxybenzoate (1.0 g, 5.5 mmol), 1-iodo-3-
(trifluoromethyl)benzene (1.8 g, 6.6 mmol), Pd2(dba)3 (504 mg, 0.55 mmol) , xphos (286 mg, 
0.60 mmol), and Cs2CO3 (3.6 g, 11.0 mmol) in dioxane (40 mL) was stirred at 90 oC under N2 
overnight. The reaction mixture was cooled to room temperature, and filtered over Celite. The 
filtrate was concentrated. The residue was dissolved in ethyl acetate (40 mL), washed with 
brine, and dried over Na2SO4. The solution was filtered, and the filtrate was concentrated. The 
residue was purified by column chromatography (PE-PE/EA=5/1) to give methyl 4-methoxy-2-
((3-(trifluoromethyl)phenyl)amino)benzoate (1.12 g, 62.7%); 1H NMR (400MHz, CDCl3): δ 9.75 
(s, 1H), 7.95-7.92 (d, J=8.8 Hz, 1H), 7.52 (s, 1H), 7.44-7.43 (m, 2H), 7.32-7.30 (d, J=6.8 Hz, 
1H), 6.73 (d, J=6.4 Hz, 1H), 6.39-6.36 (dd, J=9.2 Hz, J=2.4 Hz, 1H), 3.88 (s, 3H), 3.76 (s, 3H). 
LRMS calculated for C17H20NO3+ [M+H]+, 326.1 found 326.1. 
 Synthesis of 4-methoxy-2-((3-(trifluoromethyl)phenyl)amino)benzoic acid (TED-589-2). To 
a mixture of methyl 4-methoxy-2-((3-(trifluoromethyl)phenyl)amino)benzoate (TED-589-1, 1.12 
g, 3.38 mmol) in a mixture of dioxane/water (10 mL/10 mL) was added LiOH.H2O(1.43 g, 33.8 
mmol) at rt and the mixture was stirred for 2 h. The mixture was acidified to pH=6 with 1 M HCl, 
and the organic phase was extracted with ethyl acetate (10 mL x 2). The organic phase was 
washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated. The residue 
was purified by column chromatography (DCM/MeOH=10/1) to give 4-methoxy-2-((3-
(trifluoromethyl)phenyl)amino)benzoic acid (1.07 g, 99% yield); 
LRMS calculated for C17H20NO3+ [M+H]+, 312.1 found 312.1. 
 
Synthesis of N,4-dimethoxy-N-methyl-2-((3-(trifluoromethyl)phenyl)amino)benzamide 
(TED-589-3). To a solution of 4-methoxy-2-((3-(trifluoromethyl)phenyl)amino)benzoic acid (TED-
589-2, 1.07 g, 3.46 mmol), N,O-dimethylhydroxylamine hydrochloride (503 mg, 5.19 mmol) and 
HATU (1.97 g, 5.19 mmol) in DMF (20 mL) was added N-ethyl-N-isopropylpropan-2-amine (880 
mg, 7.0 mmol). The mixture was stirred at room temperature for 2 h. After completion of the 
reaction, ethyl acetate was added to the mixture. Then the mixture was washed with water (100 
mL x 2) and brine (100 mL). The organic phase was dried over Na2SO4, filtered and 
concentrated. The residue was purified by column chromatography (PE/EA= 3:1) to give N,4-
dimethoxy-N-methyl-2-((3-(trifluoromethyl)phenyl)amino)benzamide as a yellow oil (1.12 g, 91.3 
% yield); 1H NMR (400MHz, CDCl3): δ 8.44 (s, 1H), 7.54-7.52 (d, J=8.8 Hz, 1H), 7.41-7.40 (d, 
J=9.2 Hz,1H), 7.38-7.36 (d, J=8.0 Hz,1H), 7.29-7.26 (m, 1H), 7.20-7.18 (d, J=7.6 Hz,1H), 6.88 
(d, J=2.8 Hz, 1H), 6.46-6.43 (dd, J=11.2 Hz, J=2.4 Hz, 1H), 3.77 (s, 3H), 3.60 (s, 3H), 3.36 (s, 
3H). LRMS calculated for C17H20NO3+ [M+H]+, 355.1 found 355.1. 
 
Synthesis of 1-(4-methoxy-2-((3-(trifluoromethyl)phenyl)amino)phenyl)ethanone (TED-
589-4). To a solution of N,4-dimethoxy-N-methyl-2-((3-(trifluoromethyl)phenyl)amino)benzamide 
(TED-589-3, 400 mg, 1.13 mmol) in dry THF (20 mL) under N2 was added methylmagnesium 
bromide (10ml 1.0M in THF, 10.0 mmol) at 0oC. The mixture was stirred at 0oC for 0.5 h and 
then at room temperature for 2 h. The reaction mixture was quenched by the addition of 
saturated aqueous NH4Cl. The organic phase was extracted with ethyl acetate. The combined 
ethyl acetate layers were washed with brine, dried over anhydrous sodium sulfate, and 
concentrated. The residue was purified by column chromatography (PE/EA= 6:1) to give the 
desired product as a yellow oil (310 mg, 88.5% yield); 1H NMR (400 MHz, CDCl3): δ 10.90 (s, 
1H), 7.80-7.77 (d, J=8.8 Hz, 1H), 7.55 (s, 1H), 7.46-7.34 (m, 1H), 7.35-7.33 (d, J=6.8 Hz, 1H), 
6.70 (d, J=2.4 Hz, 1H), 6.38-6.35 (dd, J=8.8 Hz, J=2.4 Hz, 1H), 3.76 (s, 3H), 2.59 (s, 3H). LRMS 
calculated for C16H13F3NO+ [M+H]+, 310.1 found 310.1. 
 
Synthesis of 2-chloro-1-(4-methoxy-2-((3-(trifluoromethyl)phenyl)amino)phenyl)ethanone 
(6, TED-589). To a mixture of 1-(4-methoxy-2-((3-
(trifluoromethyl)phenyl)amino)phenyl)ethanone (TED-589-4, 310 mg, 1.0 mmol) in 
dichoromethane (DCM) (10 mL) were added DIEA (256 mg, 2.0 mmol) and TMSOTf (266 mg, 
1.2 mmol) at 0 oC under N2. The resulting mixture was warmed to room temperature and stirred 
for 2 h. NCS (24 mg, 0.18 mmol) was added and the mixture was stirred for another 2 h. It was 
quenched with water (10 mL), and the mixture was extracted with DCM (5mL x 3). The organic 
phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated. 
The residue was purified by prep. TLC (PE/EA=5/1) to give the crude product (207 mg). The 
compound was further purified by reverse HPLC Gilson to afford the desired product as a yellow 
solid (78 mg, 22.6% yield); 1H NMR (400MHz, CDCl3): δ 10.72 (s, 1H), 7.73-7.70 (d, J=9.2 Hz, 
1H),7.56 (s, 1H) 7.50-7.38 (m, 3H), 6.69 (s, 1H), 6.40-6.38 (d, J=8.8 Hz, 1H), 4.67 (s, 2H), 3.77 
(s, 3H); 13C NMR (400MHz, CDCl3): δ 191.67, 165.44, 150.50, 140.54, 133.67, 132.44, 132.12, 
131.79, 130.11, 126.22, 125.19, 122.49, 120.81, 120.78, 119.66, 119.62, 119.59, 110.91, 
105.99, 97.20, 55.37, 46.22. LRMS calculated for C17H19ClNO3+ [M+H]+, 344.1 found 344.1. 
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Synthesis of 2-(4-nitrophenyl)thiophene (TED-587-1). A mixture of 1-bromo-4-nitrobenzene 
(1.0 g, 5.0 mmol), thiophen-2-ylboronic acid (0.64 g, 5.0 mmol), Pd(PPh3)4 (580 mg, 0.5 mmol), 
and Na2CO3 (1.1 g, 10.0 mmol) in dioxane (40 mL) and water (5 mL) was stirred at 90 oC under 
N2 overnight. The reaction mixture was cooled to room temperature, and filtered over Celite. 
The filtrate was concentrated. The residue was dissolved in ethyl acetate (40 mL), and the 
solution was washed with brine, and dried over Na2SO4. The solution was filtered, and the 
filtrate was concentrated. The residue was purified by column chromatography (PE-
PE/EA=10/1) to give 2-(4-nitrophenyl)thiophene (0.54 g, 52.6% yield). LRMS calculated for 
C10H8NO2S+ [M+H]+, 206.0 found 206.0. 
 
Synthesis of 4-(thiophen-2-yl)aniline (TED-587-2). To a mixture of 2-(4-nitrophenyl)thiophene 
(540 mg, 2.63 mmol) in EtOH (30 mL) was added sat. NH4Cl (5 mL), followed by iron powder 
(740 mg, 13.15 mmol). The resultant mixture was heated to reflux and stirred for 30 min, and 
then cooled to rt. The mixture was filtered over celite and the filtrate was concentrated. The 
residue was dissolved in EA. The solution was washed with brine, dried over Na2SO4, and 
filtered. The filtrate was concentrated. The residue was purified by column chromatography 
(PE/EA=4:1) to afford 4-(thiophen-2-yl)aniline (360 mg, 78.3% yield). 1H NMR (400 MHz, 
CDCl3): δ 7.42-7.40 (d, J=8.4 Hz, 2H), 7.16-7.15 (m, 2H), 7.03-7.01 (m, 1H), 6.69-6.67 (d, J=8.4 
Hz, 2H), 3.72 (br, 2H). LRMS calculated for C10H10NS+ [M+H]+, 176.1 found 176.1. 
 
Synthesis of 1-(2-((4-(thiophen-2-yl)phenyl)amino)phenyl)ethanone (TED-587-3). A mixture 
of 4-(thiophen-2-yl)aniline (360 mg, 2.06 mmol), 1-(2-bromophenyl)ethanone (405 mg, 2.06 
mmol), Pd2(dba)3 (190 mg, 0.21 mmol) , xphos (150 mg, 0.32 mmol), and Cs2CO3 (1.30 g, 4.0 
mmol) in dioxane (30 mL) was stirred at 90 oC under N2 overnight. The reaction mixture was 
cooled to room temperature, and filtered over Celite. The filtrate was concentrated. The residue 
was dissolved in ethyl acetate (40 mL), and the solution was washed with brine, and dried over 
Na2SO4. The solution was filtered, and the filtrate was concentrated. The residue was purified 
by column chromatography (PE-PE/EA=8/1) to give1-(2-((4-(thiophen-2-
yl)phenyl)amino)phenyl)ethanone (130 mg, 21.5% yield). LRMS calculated for C18H16NOS+ 
[M+H]+, 294.1 found 294.1. 
 
Synthesis of 2-chloro-1-(2-((4-(thiophen-2-yl)phenyl)amino)phenyl)ethanone (7, TED-587). 
To a mixture of 1-(2-((4-(thiophen-2-yl)phenyl)amino)phenyl)ethanone (130 mg, 0.44 mmol) in 
DCM (10 mL) were added DIEA (120 mg, 0.9 mmol) and TMSOTf (150 mg, 0.66 mmol) at 0 oC 
under N2. The resulting mixture was warmed to rt and stirred for 2 h. NCS (70 mg, 0.53 mmol) 
was added and the mixture was stirred for another 2 h. It was quenched with water (10 mL), and 
the mixture was extracted with DCM (5mL x 3). The organic phase was washed with brine, dried 
over Na2SO4, and filtered. The filtrate was concentrated. The residue was purified by prep. TLC 
(PE/EA=5/1) to give the crude product (207 mg). The compound was further purified by reverse 
phase HPLC Gilson to afford the desired product as a yellow solid (54 mg, 35.2% yield); 1H 
NMR (400 MHz, CDCl3): δ 10.42 (s, 1H), 7.76-7.74 (d, J = 8.0 Hz, 1H), 7.62-7.60 (d, J = 8.4 Hz, 
2H), 7.39-7.30 (m, 2H), 7.28-7.25 (m, 4H), 7.09-7.07 (dd, J = 4.8 Hz, J = 3.6 Hz, 1H), 6.79-6.75 
(t, J = 7.2 Hz, 1H), 4.76 (s, 2H); 13C NMR (400 MHz, CDCl3): δ 193.05, 148.54, 143.93, 139.12, 
135.52, 131.30, 130.60, 128.07, 126.97, 124.50, 123.41, 122.72, 117.00, 116.26, 114.86, 46.62. 
LRMS calculated for C18H15ClNOS+ [M+H]+, 328.1 found 328.1. 
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Synthesis of 2-(3-nitrophenyl)thiophene (TED-588-1). The method was the same as TED-
587-1 to give 2-(3-nitrophenyl)thiophene (650 mg, 63.1% yield); 1H NMR (400 MHz, CDCl3): δ 
8.45 (s, 1H), 8.13-8.11 (d, J=8.4 Hz, 1H), 7.92-7.90 (d, J=7.6 Hz, 1H), 7.57-7.53 (t, J=8.0 Hz, 
1H), 7.44 (d, J=3.6 Hz, 1H), 7.39 (d, J=4.8 Hz, 1H), 7.15-7.13 (m, 1H). LRMS calculated for 
C10H8NO2S+ [M+H]+, 206.0 found 206.0. 
 
Synthesis of 3-(thiophen-2-yl)aniline (TED-588-2). The method was same as TED-587-2 to 
give 3-(thiophen-2-yl)aniline (440 mg, 78.1% yield). LRMS calculated for C10H10NS+ [M+H]+ : 
176.1, found 176.1. 
 
Synthesis of 1-(2-((3-(thiophen-2-yl)phenyl)amino)phenyl)ethanone (TED-588-3). The 
method was same as TED-587-3 to give 1-(2-((3-(thiophen-2-yl)phenyl)amino)phenyl)ethanone 
(1.4 g, 78.1% yield). LRMS calculated for C18H16NOS+ [M+H]+ : 294.1, found 294.1. 
 
Synthesis of 2-chloro-1-(2-((3-(thiophen-2-yl)phenyl)amino)phenyl)ethanone (8, TED-588). 
The method was same as 7 (TED-587) to give 2-chloro-1-(2-((3-(thiophen-2-
yl)phenyl)amino)phenyl)ethanone (27.4 mg, 61.6% yield); 1H NMR (400 MHz, CDCl3): δ 10.42 
(s, 1H), 7.76-7.74 (d, J=8.0 Hz, 1H), 7.49 (s, 1H), 7.40-7.34 (m, 3H), 7.31-7.25 (m, 3H), 7.18-
7.17 (d, J=7.2 Hz, 1H), 7.09-7.07 (m, 1H), 6.78-6.75 (m, 1H), 4.76 (s, 2H); 13C NMR (400 MHz, 
CDCl3): δ 193.09, 148.77, 143.75, 140.36, 135.82, 135.56, 131.30,129.97, 128.07, 125.51, 
123.44, 122.31, 122.09, 116.95, 116.95, 116.20, 114.76, 46.62. LRMS calculated for 
C18H15ClNOS+ [M+H]+ : 328.1, found 328.1. 
 
Synthesis Scheme of 9 (TED-549) 
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Synthesis of 5-(benzyloxy)pentan-1-ol (TED-549-1). 
To a solution of pentane-1,5-diol (5.0 g, 48.01 mmol) in DMF (50 mL) was added 60% of NaH 
(1.3 g, 33.61 mmol) at 0 oC under N2. The resulting mixture was warmed to room temperature 
and stirred for 30 min. BnBr (5.7g, 33.61 mmol) was added at 0 oC. The mixture was heated to 
50 oC under N2, and stirred for 30min. The reaction mixture was cooled to room temperature, 
and it was quenched with water (100 mL). The mixture was extracted with EA (40 mL*3). The 
organic phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was 
concentrated. The residue was purified by column chromatography (PE-PE/EA=2/1) to give 5-
(benzyloxy)pentan-1-ol (2.2 g, 33.7%); 1H NMR (400MHz, CDCl3): δ 7.26-7.34 (m, 5H), 4.50 (s, 
2H), 3.64 (t, J=6.4Hz, 2H), 3.48 (t, J=6.4Hz, 2H), 1.56-1.67 (m, 4H), 1.41-1.49 (m, 2H), 1.32 (br, 
1H). 
 
Synthesis of 5-(benzyloxy)pentyl methanesulfonate (TED-549-2). 
To a mixture of 5-(benzyloxy)pentan-1-ol (TED-549-1, 2.2 g, 11.32 mmol) in DCM (30 mL) were 
added MsCl (1.4 g, 12.45 mmol) and TEA (2.3 g, 22.64 mmol) at 0 oC under N2. The resulting 
mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was 
quenched with water (50 mL), and the mixture was extracted with DCM (30mL x 3). The organic 
phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated to 
give 5-(benzyloxy)pentyl methanesulfonate (2.5 g, 81.3%); 1H NMR (400MHz, CDCl3): δ 7.26-
7.35 (m, 5H), 4.50 (s, 2H), 4.23 (t, J=6.4Hz, 2H), 3.48 (t, J=6.4Hz, 2H), 2.99 (s, 3H), 1.76-1.80 
(m, 2H), 1.63-1.71 (m, 2H), 1.48-1.54 (m, 2H). 
 
Synthesis of 2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethanol (TED-549-3). To a mixture of 
2,2'-oxydiethanol (2.9 g, 27.53 mmol) in THF (50 mL) was added 60% of NaH (550 mg, 13.77 
mmol) at 0 oC under N2. The resulting mixture was warmed to room temperature and stirred for 
30 min. A solution of 5-(benzyloxy)pentyl methanesulfonate (TED-549-2, 2.5 g, 9.18 mmol) in 
THF (10 mL) was added and the mixture was refluxed for 3 h under N2, and then cooled to room 
temperature. The reaction mixture was quenched with water (150 mL), and the mixture was 
extracted with EA (40mL x 3). The organic phase was washed with brine, dried over Na2SO4, 
and filtered. The filtrate was concentrated. The residue was purified by column chromatography 
(PE/EA=10/1 to 1/1) to give 2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethanol (1.9 g, 73.4%); 1H 
NMR (400MHz, CDCl3): δ 7.26-7.34 (m, 5H), 4.50 (s, 2H), 3.71-3.74 (m, 2H), 3.66-3.69 (m, 2H), 
3.57-3.63 (m, 4H) , 3.47 (t, J=6.4Hz, 4H), 2.47 (br, 1H), 1.59-1.68 (m, 4H), 1.40-1.47 (m, 2H). 
 
Synthesis of 2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethyl methanesulfonate (TED-549-4). 
To a mixture of 2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethanol (TED-549-3, 1.9 g, 6.74 mmol) in 
DCM (50 mL) were added MsCl (0.92 g, 8.09 mmol) and TEA (1.4 g, 13.48 mmol) at 0 oC under 
N2. The resulting mixture was warmed to room temperature and stirred for 1 h. The reaction 
mixture was quenched with water (100 mL), and the mixture was extracted with DCM (30mL x 
3). The organic phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was 
concentrated to give 2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethyl methanesulfonate (1.8 g, 
74.1%); 1H NMR (400MHz, CDCl3): δ 7.26-7.37 (m, 5H), 4.50 (s, 2H), 4.38 (t, J=4.4Hz, 2H), 
3.76 (t, J=4.4Hz, 2H), 3.64-3.66 (m, 2H), 3.56-3.58 (m, 2H), 3.43-3.49 (m, 4H), 3.06 (s, 3H), 
1.57-1.65 (m, 4H) , 1.38-1.46 (m, 2H). 
 Synthesis of N,N-diBoc-2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethan-1-amine (TED-549-5) 
A mixture of 2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethyl methanesulfonate (TED-549-4, 1.8 g, 
5.00 mmol), HNBoc2 (1.2 g, 5.5 mmol) and K2CO3 (1.4 g, 10.00 mmol) in DMF (30 mL) was 
heated to 100 oC under N2 and the mixture was stirred for 3 h. It was then cooled to room 
temperature. The reaction mixture was quenched with water (100 mL), and extracted with EA 
(40mL x 3). The organic phase was washed with brine, dried over Na2SO4, and filtered. The 
filtrate was concentrated. The residue was purified by column chromatography (PE/EA=10/1 to 
3/1) to give N,N-diBoc-2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethan-1-amine (2.0 g, 83.1%); 1H 
NMR (400MHz, CDCl3): δ 7.26-7.34 (m, 5H), 4.50 (s, 2H), 3.74-3.80 (m, 2H), 3.53-3.63(m, 6H), 
3.42-3.48 (m, 4H), 1.58-1.65 (m, 4H), 1.49 (s, 18H), 1.39-1.45 (m, 2H). 
 
Synthesis of N-(2-(2-((5-hydroxypentyl)oxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (TED-549-6) 
A mixture of ditert-butyl (2-(2-((5-(benzyloxy)pentyl)oxy)ethoxy)ethyl)carbamate (TED-549-5, 2.0 
g, 4.15 mmol) and 10% of Pd/C (300 mg) in MeOH (100 mL) was stirred for 18 h under H2. The 
reaction mixture was filtered through Celite and the filtrate was concentrated. The residue was 
dissolved in DCM (10 mL) and 6M HCl in dioxane (5 mL) was added. The resulting mixture was 
stirred at room temperature for 2 h and then the solvent was removed. The residue was 
dissolved in DMF (15 mL), and TEA (1.03 g, 10.02 mmol) was added, followed by HATU (1.16 
g, 3.06 mmol). The resulting mixture was stirred at room temperature for 2 h, and concentrated. 
The crude product was purified by prep-HPLC to give N-(2-(2-((5-
hydroxypentyl)oxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 
(120 mg, 6.9%); 1H NMR (400MHz, CD3OD): δ 4.47-4.50 (m, 1H), 4.29-4.32 (m, 1H), 3.48-3.59 
(m, 10H), 3.36 (t, J=5.6Hz, 2H), 3.18-3.23 (m, 1H), 2.90-2.95 (m, 1H), 2.70 (t, J=12.8Hz, 1H), 
2.21 (t, J=7.2Hz, 2H), 1.54-1.75 (m, 8H), 1.40-1.48 (m, 4H). LRMS calculated for C19H36N3O5S+ 
[M+H]+, 418.6, found 418.2. 
 
Synthesis of tert-butyldimethyl(3-nitrophenoxy)silane (TED-549-7) 
To a solution of 3-nitrophenol (1.0 g, 7.20 mmol) in DCM (20 mL) were added TBSCl (1.2 g, 
7.92 mmol) and imidazole (979 mg, 14.40 mmol) at room temperature. The resulting mixture 
was stirred for 2 h and quenched with water (40 mL). It was extracted with DCM (30 mL x 3). 
The organic phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was 
concentrated. The residue was purified by column chromatography (PE-PE/EA=2/1) to give tert-
butyldimethyl(3-nitrophenoxy)silane (1.3 g, 71.4%); 1H NMR (400MHz, CDCl3): δ 7.83 (d, 
J=8.0Hz, 1H), 7.66 (t, J=2.4Hz, 1H), 7.38 (t, J=8.0Hz, 1H), 7.16 (d, J=8.0Hz, 1H), 1.00 (s, 9H), 
0.24 (s, 6H), 1.41-1.49 (m, 2H), 1.32 (br, 1H). 
Synthesis of 3-((tert-butyldimethylsilyl)oxy)aniline (TED-549-8) 
To a mixture of tert-butyldimethyl(3-nitrophenoxy)silane (TED-549-7, 1.3 g, 5.14 mmol) in MeOH 
(20 mL) was added 10% of Pd/C (200 mg). The resulting mixture was stirred at room 
temperature overnight under H2 (1 atm). The reaction mixture was filtered through Celite and the 
filtrate was concentrated to give 3-((tert-butyldimethylsilyl)oxy)aniline (1.1 g, 95.7%); LRMS 
calculated for C12H22NOSi+ [M+H]+, 224.4, found 224.3. 
 
Synthesis of 1-(2-((3-((tert-butyldimethylsilyl)oxy)phenyl)amino)phenyl)ethan-1-one (TED-
549-9) 
The mixture of 3-((tert-butyldimethylsilyl)oxy)aniline (TED-549-8, 600 mg, 2.69 mmol), 1-(2-
bromophenyl)ethanone (562 mg, 2.83 mmol), Pd2(dba)3 (246 mg, 0.27 mmol) , xphos (257 mg, 
0.54 mmol), and Cs2CO3 (1.30 g, 4.04 mmol) in dioxane (15 mL) was heated to 90 oC under N2, 
and it was stirred for 2 h. The reaction mixture was cooled to room temperature, filtered through 
Celite and the filtrate was concentrated. The residue was dissolved in EA (40 mL), washed with 
brine, and dried over Na2SO4. It was filtered, and the filtrate was concentrated. The residue was 
purified by column chromatography (PE-PE/EA=20/1) to give 1-(2-((3-((tert-
butyldimethylsilyl)oxy)phenyl)amino)phenyl)ethan-1-one (410 mg, 44.6%); 1H NMR (400MHz, 
CDCl3): δ 10.47 (s, 1H), 7.81 (d, J=8.4Hz, 1H), 7.28-7.33 (m, 2H), 7.18 (t, J=8.0Hz, 1H), 6.85 (d, 
J=7.6Hz, 1H), 6.71-6.74 (m, 2H), 6.61 (d, J=8.4Hz, 1H), 2.64 (s, 3H), 0.98 (s, 9H), 0.21 (s, 6H). 
 
Synthesis of 1-(2-((3-hydroxyphenyl)amino)phenyl)ethan-1-one (TED-549-10) 
To a solution of 1-(2-((3-((tert-butyldimethylsilyl)oxy)phenyl)amino)phenyl)ethan-1-one (TED-
549-9, 100 mg, 0.29 mmol) in THF (2 mL) was added 1M TBAF in THF (0.35 mL, 0.35 mmol) 
dropwise at room temperature. The resulting mixture was stirred for 1 h and quenched with 
water (20 mL). The mixture was extracted with EA (10 mL x 3), and the organic phase was 
washed with brine, and dried over Na2SO4. It was filtered, and the filtrate was concentrated. The 
residue was purified by prep-TLC (DCM/MeOH=10/1) to give 1-(2-((3-
hydroxyphenyl)amino)phenyl)ethan-1-one (52 mg, 70.8%); 1H NMR (400MHz, CDCl3): δ 10.49 
(s, 1H), 7.82 (d, J=8.0Hz, 1H), 7.32 (d, J=7.6Hz, 2H), 7.20 (t, J = 8.0 Hz, 1H), 6.83 (d, J=8.0Hz, 
1H), 6.73-6.77 (m, 2H), 6.58 (d, J=8.0Hz, 1H), 2.65 (s, 3H). LRMS calculated for C14H14NO2+ 
[M+H]+, 228.3 found 228.1. 
 
Synthesis of N-(2-(2-((5-(3-((2-acetylphenyl)amino)phenoxy)pentyl)oxy)ethoxy)ethyl)-5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (TED-549-11) 
To a mixture of N-(2-(2-((5-hydroxypentyl)oxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (TED-549-6, 50 mg, 0.12 mmol), 1-(2-((3-
hydroxyphenyl)amino)phenyl)ethan-1-one (TED-549-10, 35 mg, 0.16 mmol), and PPh3 (63 mg, 
0.24 mmol) in dioxane (3 mL) was added DIAD (53 mg, 0.26 mmol) at 0 oC under N2, The 
resulting mixture was warmed to room temperature and stirred overnight. The reaction mixture 
was quenched with water (5 mL), and extracted with EA (10 mL x 2). The organic phase was 
washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated. The residue 
was purified by prep-TLC (DCM/MeOH=5/1) to give N-(2-(2-((5-(3-((2-
acetylphenyl)amino)phenoxy)pentyl)oxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (42 mg, 46% yield); 1H NMR (400MHz, CDCl3): δ 10.50 (s, 1H), 
7.81 (d, J = 8.0 Hz, 1H), 7.26-7.34 (m, 2H), 7.12-7.24 (m, 1H), 6.72-6.85 (m, 2H), 6.63-6.66 (m, 
1H), 6.48-6.58 (m, 1H), 6.12 (s, 1H), 5.22 (s, 1H), 4.86-4.97 (m, 1H), 4.46-4.49 (m, 1H), 4.28-
4.31 (m, 1H), 3.88-3.96 (m, 2H), 3.44-3.64 (m, 10H), 3.10-3.14 (m, 1H), 2.87-2.91 (m, 1H), 2.70-
2.74 (m, 1H), 2.64 (s, 2H), 2.15-2.26 (m, 2H), 1.56-1.84 (m, 12H). LRMS calculated for 
C33H47N4O6S+ [M+H]+, 627.3 found 627.4. 
 
Synthesis of N-(2-(2-((5-(3-((2-(2-
chloroacetyl)phenyl)amino)phenoxy)pentyl)oxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (9, TED-549) 
The method was the same as 4 (TED-548) to give N-(2-(2-((5-(3-((2-(2-
chloroacetyl)phenyl)amino)phenoxy)pentyl)oxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (11 mg); 1H NMR (400MHz, CDCl3): δ 10.33 (s, 1H), 7.71-7.80 (m, 
2H), 6.72-6.85 (m, 4H), 6.60-6.62 (m, 3H), 6.30-6.39 (m, 2H), 5.44 (s, 2H), 4.88-5.09 (m, 3H), 
4.76 (s, 2H), 4.70 (s, 1H), 4.47 (s, 2H), 4.29 (m, 2H), 3.92-4.00 (m, 5H), 3.43-3.60 (m, 25H), 
3.05-3.15 (m, 2H), 2.86-2.91 (m, 2H), 2.65-2.74 (m, 3H), 2.21 (br, 6H). LRMS calculated for 
C33H46ClN4O6S+ [M+H]+, 661.3, found 661.2. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Fluorescence polarization, biolayer interferometry, and cell biological studies results are 
representatives of at least three independent studies, performed in duplicates. 
Crystal structure statistics are available in Supplementary Table 2. 
DATA AND SOFTWARE AVAILABILITY 
The atomic coordinates of human TEAD2 Yap-binding domain covalently bound to compound 2, 
reported in this paper, are deposited to the Protein Data Bank under accession code 6E5G. 
ADDITIONAL RESOURCES 
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Supplementary Table 2. X-ray crystallographic data-collection and refinement statistics of TEAD2 
covalently bound to 2 (TED-347), related to Figure 5. 
 
 TEAD2 covalently bound to 2 (TED-
347) 
Data collection 
Wavelength (Å) 0.97625 
Space group C2 
Cell dimensions 
a, b, c (Å) 123.76   61.23   79.84 
α, β, γ(º 90.00  116.89   90.00 
Resolution (Å) 48.17 – 2.43 
Rsym 0.098 (1.198) 
Rmeas 0.116 (1.423) 
Rpim 0.061 (0.760) 
CC1/2 0.996 (0.601) 
I/σ(I) 9.8 (1.0) 
Completeness (%) 99.7 (100.0) 
Multiplicity 3.6 (3.5) 
Refinement 
Resolution (Å) 
 
38.89 – 2.43 (2.56 – 2.43) 
No. unique reflections 20132 
Rwork 0.2205 
Rfree 0.2678 
RMS deviations 
Bond lengths (Å) 0.003 
Bond angles (º) 0.601 
No. atoms 
Protein 3400 
Ligand 52 
B-factors (Å2) 
Protein/ligand/ions 61.82 
Ramachandran plot 
Favored (%) 96.3 
Allowed (%) 3.2 
MolProbity score  1.21 
Rotamer outliers (%) 0.27 
*Highest-resolution shell values are shown in parentheses. 
  
 Supplementary Figure 1. TEAD4 Cys-367 is reactive to iodoacetamide, related to Figure 4. A 
sample of 5 µM TEAD4 was reacted with 12.5, 50, and 200 µM iodoacetamide at 4°C for (A) 30 min, 
(B) 6 h, and (C) 24 h. Wild-type TEAD4 YBD construct showed an apparent MW of 25952, and the 
iodoacetamide adduct was +57. (D) A sample of 5 µM TEAD4 Cys367Ser mutant was reacted with 
12.5, 50, and 200 µM iodoacetamide at 4°C for 24h. TEAD4 YBD Cys367Ser mutant construct 
showed an apparent MW of 25936. (E) TEAD4 was incubated with increasing concentration of 
iodoacetamide for 24 h at 4°C followed by addition of FAM-Yap60-99 to measure changes in 
fluorescence polarization.  
 
Supplementary Figure 2. Synthetic derivatives of 2 (TED-347), related to Figures 2 and 3.  (A) 
TEAD4 was incubated with increasing concentration of compounds for 24 h at 4°C followed by 
addition of FAM-Yap60-99 for fluorescence polarization measurement (mean ± s.d.; n = 3). (B) TEAD4 
Cys367Ser mutant was incubated with increasing concentrations of compounds for 24 h at 4°C and 
then interacted with fluorescently labeled Yap peptide for FP measurement (mean ± s.d.; n = 3). (C) 
10 µM TEAD4 was incubated with 200 µM compounds for 24 h at 4°C, and then analyzed by ESI 
mass spectrometry. (D) 10 µM TEAD4 Cys367Ser mutant was incubated with 200 µM compounds 
for 24 h at 4°C and then analyzed by ESI mass spectrometry. (E) His-TEAD2 was incubated with 
increasing concentration of compounds for 24 h at 4°C followed by addition of FAM-Yap60-99 for 
fluorescence polarization measurement (mean ± s.d.; n = 3). (F) Time-dependent inhibition of 
TEAD4 by 4 (TED-548) was assessed by the FP assay at 10 different concentrations (0.1-100 µM) 
after 0.5, 6, 24 and 48 h incubations at 4°C (mean ± s.d.; n = 3). (G) Time-dependent inhibition of 
TEAD4 by 5 (TED-551) was assessed by the FP assay at 10 different concentrations (0.1-100 µM) 
after 0.5, 6, 24 and 48 h incubations at 4°C (mean ± s.d.; n = 3).  (H) Time-dependent inhibition of 
TEAD4 by 6 (TED-589) was assessed by the FP assay at 10 different concentrations (0.1-100 µM) 
after 0.5, 6, 24 and 48 h incubations at 4°C (mean ± s.d.; n = 3).  (I) Time-dependent inhibition of 
TEAD4 by 4 (TED-548) was assessed by the FP assay at 10 different concentrations (0.1-100 µM) 
after 0.5, 6, 24, and 48 h incubations at 4°C. The observed rate of inactivation (kobs) was calculated 
for each concentration of compound and is plotted against the concentration of compound (mean ± 
s.d.; n = 3). (J) Time-dependent inhibition of TEAD4 by 5 (TED-551) was assessed by the FP assay 
at 10 different concentrations (0.1-100 µM) after 0.5, 6, 24, and 48 h incubations at 4°C. The 
observed rate of inactivation (kobs) was calculated for each concentration of compound and is plotted 
against the concentration of compound (mean ± s.d.; n = 3). (K) Time-dependent inhibition of TEAD4 
by 6 (TED-589) was assessed by the FP assay at 10 different concentrations (0.1-100 µM) after 0.5, 
6, 24, and 48 h incubations at 4°C. The observed rate of inactivation (kobs) was calculated for each 
concentration of compound and is plotted against the concentration of compound (mean ± s.d.; n = 
3).  
Supplementary Figure 3. Compound 
2 (TED-347) does not Inhibit TEAD 
mutant transcriptional activity and 
protein-protein interactions in cell 
culture, related to Figure 6. (A) The 
activity of the TEAD4 luciferase reporter 
was measured in HEK-293 cells at 24 h 
treated with either vehicle or compound 
2 (TED-347); mean ± s.d.; n = 3 
replicates. (B) The activity of the TEAD4 
luciferase reporter was measured in 
HEK-293 cells treated with either 
vehicle or compound 2 (TED-347); 
mean ± s.d.; n = 2 replicates.  (C) 
Coomassie-stained gel of the pull-down 
sample.  The pull-down shows little 
background suggesting that the 
compound is likely selective to TEAD4. 
  
 Supplementary Figure 4. Cell Viability Studies in Human Astrocytes, related to Figure 7.  
Human astrocytes cells were plated 24 h before treatment in collagen I coated 96-well plates in 
Dulbecco's modified Eagle's medium, supplemented with 20 µg/mL insulin, 5 µg/mL N-
acetylcysteine, 10% fetal bovine serum, 10 µM hydrocortisone and antibiotics; then treated with 
DMSO or TED-347 at indicated concentrations for 72 h at 37°C and 5% CO2 in a humidified 
incubator. Stock MTS (Promega) solution (20 µL per 100 µL medium) was added to all wells of an 
assay, and plates were incubated at 37°C for 4 h, and read on a BioTek Synergy 2 reader, using a 
test wavelength of 490 nm; mean ± s.d.; n = 2 replicates. 
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